var title_f8_19_8496="CT chondro";
var content_f8_19_8496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography image of mesenchymal chondrosarcoma arising from the posterior chest wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The large tumor contains extensive areas of matrix mineralization. Aggressive lytic destruction of the posterior part of the rib and the thoracic vertebral body is noted. Histology of these lytic areas shows undifferentiated small round cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.TheOncologist.com\">",
"      file://www.TheOncologist.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8496=[""].join("\n");
var outline_f8_19_8496=null;
var title_f8_19_8497="Severe spinal stenosis in Paget disease";
var content_f8_19_8497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe spinal stenosis in Paget disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paget disease affecting L4 and L5, with overgrowth of L4, extension of pagetic changes into the posterior elements of the spine and compression. This man presented with severe spinal stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Margaret Seton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8497=[""].join("\n");
var outline_f8_19_8497=null;
var title_f8_19_8498="Patient information: Chronic granulomatous disease (The Basics)";
var content_f8_19_8498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/23/4466\">",
"         Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/17/14611\">",
"         Patient information: Pneumonia in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14225\">",
"         Patient information: Pneumonia prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/55/15217\">",
"         Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic granulomatous disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-granulomatous-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9359483\">",
"      <span class=\"h1\">",
"       What is chronic granulomatous disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic granulomatous disease (called &ldquo;CGD&rdquo; here) is a serious disease that causes infections, inflammation, and other symptoms. In a person who has CGD, some of the cells that normally fight infection do not work correctly. This makes the person likely to get many infections. These infections can be very serious. Sometimes, they even cause death.",
"     </p>",
"     <p>",
"      CGD is a rare disease. It runs in families. Because CGD causes so many infections, doctors usually find it when the person with CGD is a child. CGD is more common in boys, but girls can also get it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9359498\">",
"      <span class=\"h1\">",
"       What are the symptoms of CGD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pneumonia &ndash; This is a lung infection that causes coughing, fever, and trouble breathing. People with CGD can get pneumonia many times. &nbsp;",
"       </li>",
"       <li>",
"        Skin infections. These include: &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Cellulitis, a skin infection that causes redness, pain, and swelling",
"       </li>",
"       <li>",
"        Impetigo, a skin infection that causes red bumps on the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Swollen lymph nodes &ndash; These are bean-shaped organs that are part of the body&rsquo;s infection-fighting system. There are lymph nodes behind the ears, in the neck, and in many other areas of the body. If a person is sick, lymph nodes can swell up and hurt. &nbsp;",
"       </li>",
"       <li>",
"        Abscesses &ndash; Swollen, red, and painful areas on the skin. A common place to get these is around the rectum. &nbsp;",
"       </li>",
"       <li>",
"        Growth problems &ndash; A child with CGD might be smaller than other children the same age.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with CGD might not have symptoms, such as a fever, even if they have severe infections. They often have infections that come back again and again. For example, a child with CGD might get pneumonia several times. Or he or she might have many skin infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9359513\">",
"      <span class=\"h1\">",
"       Is there a test for CGD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your child&rsquo;s symptoms and do an exam. He or she will order blood tests. The tests can show:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with the body&rsquo;s infection-fighting system &ndash; This is also called the &ldquo;immune system.&rdquo; In people who have CGD, some of the cells in the immune system do not work correctly.",
"       </li>",
"       <li>",
"        Abnormal genes &ndash; People with CGD have abnormal genes. A type of blood test called a &ldquo;genetic test&rdquo; can show if the genes are abnormal. If they are, this is good proof of CGD.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If someone in your family had CGD, your child should have a blood test soon after he or she is born. If you are pregnant and know someone in your family had CGD, you can have tests before your baby is born. These tests can show if the baby has CGD. If doctors find CGD before a baby is born, they can make plans to prevent infections and treat the disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9359528\">",
"      <span class=\"h1\">",
"       How is CGD treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines &ndash; These can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Help prevent infection",
"       </li>",
"       <li>",
"        Treat any infections that happen",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bone marrow transplant &ndash; This treatment can cure CGD. A bone marrow transplant is a procedure that replaces abnormal or missing cells in the bone marrow with healthy cells. The bone marrow is the tissue in the middle of certain bones. Bone marrow makes blood cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a person with CGD gets a transplant of healthy bone marrow, this can help his or her body make new blood cells. The new blood cells from the transplant include normal infection-fighting cells. If a bone marrow transplant works, a person who had CGD can fight off infections like a healthy person. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9359543\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       Patient information: Pneumonia in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=see_link\">",
"       Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"       Patient information: Pneumonia prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=see_link\">",
"       Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/19/8498?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83030 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8498=[""].join("\n");
var outline_f8_19_8498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9359483\">",
"      What is chronic granulomatous disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9359498\">",
"      What are the symptoms of CGD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9359513\">",
"      Is there a test for CGD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9359528\">",
"      How is CGD treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9359543\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=related_link\">",
"      Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=related_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=related_link\">",
"      Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8499="Normal wrist x-ray";
var content_f8_19_8499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of a normal wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 532px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph of the normal right wrist is displayed in the AP (A), oblique (B), and lateral (C) projections.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8499=[""].join("\n");
var outline_f8_19_8499=null;
var title_f8_19_8500="Proof, p-values, and hypothesis testing";
var content_f8_19_8500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proof, p-values, and hypothesis testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8500/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8500/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8500/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8500/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8500/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8500/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/19/8500/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concepts around biostatistics are frequently confusing to clinicians. The meaning of a p-value in particular is commonly misunderstood and yet is central to the way most clinicians interpret the results of scientific studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8500/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This review will discuss the correct interpretation of p-values and confidence intervals, the idea of proof, and the understanding of power calculations in negative studies. A general discussion of the meaning of biostatistical terms is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROOF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In scientific and medical endeavors, a common question to be addressed is \"what constitutes proof?\" How do we decide when the evidence for or against a hypothesis is adequate to consider the matter proven?",
"   </p>",
"   <p>",
"    Certain methodologies of clinical trials are considered \"stronger\" than other methodologies. For instance, randomized clinical trials are generally considered better evidence than case control studies. Proof, however, never exists in a single trial result or a single piece of evidence. Proof is a human concept having to do with the rational thought process. Information may be sufficient to allow one person to consider something proven where another will not.",
"   </p>",
"   <p>",
"    As an example, there is no evidence from clinical trials in humans that cigarette smoking causes lung cancer. However, evidence from epidemiologic studies overwhelmingly shows a relationship between smoking and lung cancer. A dose-response relationship in these studies and evidence from animal studies provide strong support for the relationship having biologic plausibility and being causal (ie, smoking is not just associated with lung cancer but is a cause of lung cancer). Most people consider it proven that smoking causes lung cancer despite the absence of clinical trials in humans.",
"   </p>",
"   <p>",
"    In contrast, there are randomized trials of homeopathic preparations (essentially extremely dilute preparations that on average will have no molecules of any of the original \"therapeutic\" substance remaining) that are claimed to have \"proven\" the effectiveness of the substance. Although these studies may have achieved a p-value less than 0.05 (see",
"    <a class=\"local\" href=\"#H7\">",
"     'P-values'",
"    </a>",
"    below), a much higher statistical standard of proof may be appropriate given the implausibility of the underlying hypothesis.",
"   </p>",
"   <p>",
"    Thus, when discussing whether an issue in medicine has been proven, disproven, or remains uncertain, it is important to remember that no single statistic or value will provide the answer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STATISTICAL TESTS AND THE NULL HYPOTHESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Samples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statistical testing is generally performed to deal with the problem of random variation in samples. Because of random variation, a sample is likely to differ in various ways from the population from which it was selected. Statistical testing is used to estimate the effects of random variation in samples, and to predict how likely it is that the results in the sample accurately reflect what would be seen in the entire population. In general, the size of the sample, but not the size of the population, matters when considering random variation.",
"   </p>",
"   <p>",
"    As an example, if three people from a population of 1000 are randomly selected and given a drug for high blood pressure, the results in those three people are unlikely to accurately reflect what would be seen in the entire population. In contrast, if 500 people were randomly selected, the results would likely reflect the underlying population with relatively good accuracy whether selected from a group of 1000 or 1,000,000 people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Null hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When statistical tests are used in research, it is generally to decide whether or not to reject the \"null hypothesis.\" The null hypothesis is the hypothesis that will be statistically assumed until some level of statistical evidence is reached to allow a decision to reject it. Although this notion feels awkward, it is needed to allow statistical tests to perform as expected, and understanding it is required for understanding the use of p-values in hypothesis testing. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'P-values'",
"    </a>",
"    below.) Generally, the null hypothesis is the theory that the exposure or intervention that is being studied is not associated with the outcome of interest. Thus, if a certain level of statistical significance is reached the null hypothesis will be rejected, otherwise the null hypothesis will not be rejected.",
"   </p>",
"   <p>",
"    As an example, consider a study looking at the effect of beta blockade on mortality in heart failure. The null hypothesis would be that beta blockade has no different effect on mortality from placebo. Even if beta blockers really have no effect on mortality, because of random variation in the actual study, the mortality rates in patients receiving beta blockers will likely not be the same as in patients receiving placebo. Thus, some method is needed to decide how different is \"different enough\" to reject this null hypothesis and conclude that the null hypothesis is probably false. Statistical tests are used for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXPLANATION FOR THE RESULTS OF A STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a study has a positive or negative result, one or more of the following four possible explanations will explain the outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Truth &mdash; The conclusion of the study may accurately reflect the answer to the underlying question that was being asked.",
"     </li>",
"     <li>",
"      Bias &mdash; There may be one or more errors in the way the study was performed that distorted the results and affected the conclusions.",
"     </li>",
"     <li>",
"      Confounding &mdash; There may be one or more variables that are associated both with the exposure being studied and also with the outcome of interest that affected the results of the study.",
"     </li>",
"     <li>",
"      Chance &mdash; Random variations that occurred within the sample of the population being studied may lead to erroneous conclusions. If random chance leads to a mistaken conclusion that there was an effect, the mistake is called a type 1 error (alpha error); if random chance leads to a mistaken conclusion that there was no effect, the mistake is called a type 2 error (beta error).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     P-VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once data are gathered from a study, statistical testing is performed on the results. A statistical test looks at the likelihood that a certain result would have occurred given some assumptions about the underlying population being studied. The statistical test calculated from the underlying data and the assumptions is generally translated into a p-value.",
"   </p>",
"   <p>",
"    A p-value is a measure of the effect of chance within a study. It is",
"    <strong>",
"     not",
"    </strong>",
"    the probability that the result of the study is true or correct. Instead, it is the probability that if the null hypothesis (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Null hypothesis'",
"    </a>",
"    above) were true, and if the results were not affected by bias or confounding, that we would have seen a result as extreme or more extreme than the one seen in the study.",
"   </p>",
"   <p>",
"    Thus, if we perform a methodologically perfect study of the effect of beta blockers on mortality in heart failure, find a relative risk for death of 0.75 in treated patients, and the p-value is 0.03, that means that if there were no effect of beta blockers we would have expected to get a relative risk &le;0.75 only 3 percent of the time. The p-value says nothing directly about the probabilities that we are actually interested in: the probability that beta blockers actually work or the probability that the relative risk is really 0.75. Those probabilities are never knowable from a single study. If the prior probability (the probability before the study was performed) that beta blockers affect mortality was very low, then even after the study was performed and resulted in a p-value of 0.03, the likelihood that beta blockers affect mortality would be much lower than 97 percent. In contrast, if the prior probability was very high (perhaps because of evidence from other studies or biologic plausibility), then the probability that beta blockers affect mortality after the above study was performed would be higher than 97 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONFIDENCE INTERVALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confidence intervals are a way to show the range of values that could be considered reasonably likely after statistics are performed on gathered data. Similar to the issue with p-values discussed above, and despite their name, confidence intervals cannot be used to directly infer how confident one should be in a result. As in the discussion above, consider a study that finds that patients treated with beta blockers have a relative risk of mortality of 0.75 with a 95 percent confidence interval (CI) from 0.7 to 0.8. Even if the study is methodologically correct, this does",
"    <strong>",
"     not",
"    </strong>",
"    mean that there is only a 5 percent chance that the real relative risk is below 0.7 or above 0.8. Instead it means that in correctly performed studies we would expect the CI to surround the true value for the relative risk 95 percent of the time. The difference between these two views, as is discussed above, is that the actual likelihood that the relative risk is between 0.7 and 0.8 depends upon the prior likelihood (before the study was performed) that the relative risk was in that range. If it were very unlikely prior to the study, then the likelihood after the study would not be 95 percent despite the apparent meaning of the term \"confidence interval.\"",
"   </p>",
"   <p>",
"    However, because it may be very difficult to know the prior probability, confidence intervals are often interpreted as representing a range of believable values. This is particularly useful in deciding whether a study had adequate numbers of patients to answer a question. As an example, if the above CI for the relative risk ranged from 0.5 to 1.12, the study might have been reported as \"negative\" when in reality the study was simply too small to answer the clinical question. A reduction in mortality of 50 percent would clearly be clinically meaningful, and an increase in mortality of 12 percent would likely also be meaningful. If, instead, the relative risk in the study were 0.99 with a CI from 0.97 to 1.01, it would probably be felt that it was unlikely that the real relative risk would be so high or low as to be clinically important.",
"   </p>",
"   <p>",
"    Again, though, the interpretation of confidence intervals, like the interpretation of p-values, depends upon a consideration of the totality of evidence for or against a hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STATISTICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of a specific cutoff point for a p-value or degree of confidence for a confidence interval is arbitrary. Although a p-value of 0.05 (and the corresponding choice of a 95 percent confidence interval) is conventional, there is no particular reason why a p-value of 0.02 and a corresponding 98 percent confidence interval could not be the standard for calling a result \"statistically significant.\"",
"   </p>",
"   <p>",
"    However, although the choice is arbitrary, if we use p-values to decide the statistical significance of a result, some choice is required and it must be adhered to so as to achieve the desired result of having the rate of studies that show positive results due to chance alone be predictable. If we want to know that the rate of such erroneous positive results is 5 percent, we must treat both 0.001 and 0.05 as results that are statistically significant. We must also then state that a result with a p-value of 0.06 is not statistically significant.",
"   </p>",
"   <p>",
"    Although the result where the p-value is 0.001 is less likely to be due to chance (all other things being equal) than one where it is 0.05, and a result with a p-value of 0.06 is only slightly more likely to be due to chance than where it was 0.05, if we try to use these numbers in any way other than as falling on one side or the other of a bright line (arbitrarily p = 0.05), we will no longer be able to say with certainty what percentage of studies that had statistically significant results was really the result of type 1 errors.",
"   </p>",
"   <p>",
"    Despite this loss of predictability, it is common and common sense to take very small p-values as stronger evidence in support of a hypothesis than p-values close to 0.05.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POWER IN A NEGATIVE STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Power is the statistical probability of avoiding a type 2 error in a study. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Explanation for the results of a study'",
"    </a>",
"    above.) That is, it is the probability that a study will not mistakenly accept the null hypothesis and conclude that there was no effect or difference when there really was one.",
"   </p>",
"   <p>",
"    Whenever a study finds no statistically significant difference, the issue of whether there was \"adequate power\" is raised, since one possible explanation for the result was that a small sample size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    random chance led to a failure to detect a difference that really existed. This issue feels particularly pressing when the point estimate found in the study appears clinically important. In the above hypothetical study, a relative risk for mortality of 0.75 with a 95% CI of 0.5-1.12 would not be statistically significant; however, the point estimate of a 25 percent reduction in mortality would clearly be clinically meaningful if true.",
"   </p>",
"   <p>",
"    It is possible to calculate the power a study has to find a given result (for instance a 25 percent reduction in mortality) given a particular sample size (and also given the underlying variation in the population). Power calculations are useful in the design of studies to decide whether a study is large enough to have a reasonable chance of finding a positive result or to calculate the number of patients required to achieve a certain power.",
"   </p>",
"   <p>",
"    However, when papers try to deal with the issue of \"adequate power\" after a negative study result by performing a power calculation using the point estimate found in the study, the result is meaningless. The power in such a calculation will",
"    <strong>",
"     always",
"    </strong>",
"    be less than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8500/abstract/3\">",
"     3",
"    </a>",
"    ]. Instead, as discussed above, the way to decide after the fact whether a negative study had sufficient power is to look at the confidence intervals and see whether clinically important values exist within the range of the statistically likely values represented by the confidence interval. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Confidence intervals'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proof is a human concept and never comes from a single piece of evidence or a statistical test. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Proof'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In any study, the possible explanations for the result seen are: truth, bias, confounding, and chance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Explanation for the results of a study'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A p-value is not a direct measure of the likelihood that a given result from a study is correct, even if the study is methodologically flawless. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'P-values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After finding a negative result in a study, look at the confidence interval to decide if the study had adequate power; do not look at power calculations to decide this. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Confidence intervals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8500/abstract/1\">",
"      Davidoff F. Standing statistics right side up. Ann Intern Med 1999; 130:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8500/abstract/2\">",
"      Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999; 130:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8500/abstract/3\">",
"      Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121:200.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2777 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8500=[""].join("\n");
var outline_f8_19_8500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROOF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STATISTICAL TESTS AND THE NULL HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Samples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Null hypothesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXPLANATION FOR THE RESULTS OF A STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      P-VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONFIDENCE INTERVALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STATISTICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POWER IN A NEGATIVE STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8501="Atovaquone: Pediatric drug information";
var content_f8_19_8501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atovaquone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"    see \"Atovaquone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/24/16772?source=see_link\">",
"    see \"Atovaquone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mepron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mepron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12669219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) (CDC, 2009): Treatment: 30-40 mg/kg/day divided twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"      see \"Atovaquone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1 to &lt;3 months: 30-40 mg/kg/day divided twice daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-23 months: 45 mg/kg/day divided twice daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;24 months: 30-40 mg/kg/day divided twice daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-3 months: 30 mg/kg/day once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4-24 months: 45 mg/kg/day once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;24 months: 30 mg/kg/day once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     , prophylaxis (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 months: 30 mg/kg once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-24 months: 45 mg/kg once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;24 months: 30 mg/kg once daily (maximum dose: 1500 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Babesiosis: 40 mg/kg/day divided twice daily (maximum dose: 1500 mg/day) with azithromycin 12 mg/kg/day once daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents 13-16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 750 mg/dose twice daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     encephalitis (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 750 mg 4 times daily or 1500 mg twice daily for at least 6 weeks after resolution of signs and symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suppression after treatment: 750 mg 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Babesiosis: 750 mg/dose twice daily for 7-10 days with azithromycin; 600 mg once daily for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mepron&reg;: 750 mg/5 mL (5 mL, 210 mL) [contains benzyl alcohol; citrus flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or a high-fat meal; gently shake suspension before using",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) and second-line treatment of mild to moderate PCP in patients intolerant of trimethoprim/sulfamethoxazole (TMP/SMX) (FDA approved in ages &ge;13 years and adults); mild to moderate PCP is defined as an alveolar-arterial oxygen diffusion gradient &le;45 mm Hg and PaO",
"     <sub>",
"      2",
"     </sub>",
"     &ge;60 mm Hg on room air; patients intolerant of TMP/SMX are defined as having a significant rash (ie, Stevens-Johnson-like syndrome), neutropenia, or hemolysis; has also been used for the treatment of babesiosis and the prevention of first episode of toxoplasmosis in HIV-infected children and adults",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyper-/hypoglycemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, anorexia, constipation, diarrhea, heartburn, nausea, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Oral moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, allergic reaction, angioedema, erythema multiforme, hepatitis (rare), hypersensitivity reactions, liver failure (rare), methemoglobinemia, pancreatitis, skin desquamation, Stevens-Johnson syndrome, throat tightness, thrombocytopenia, urticaria, vortex keratopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atovaquone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For patients who have difficulty taking atovaquone with food or who have chronic diarrhea, stomach or intestinal problems which may result in drug malabsorption, parenteral therapy with other agents should be considered since a low serum atovaquone concentration could lead to treatment failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical experience with atovaquone has been limited to patients with mild to moderate PCP; treatment of more severe episodes of PCP has not been systematically studied",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Suspension contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Separate administration of atovaquone and etoposide by at least 1-2 days. Avoid concomitant administration of atovaquone and etoposide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Atovaquone may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food increases bioavailability of atovaquone suspension 1.4-fold over that achieved in a fasting state or up to 3-fold with a high fat meal",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6264005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies of atovaquone in pregnant women. Use in pregnant women only if the potential benefit outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver enzymes, serum chemistries, serum amylase",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The mechanism of action against",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     has not been fully elucidated; in",
"     <i>",
"      Plasmodium",
"     </i>",
"     species, atovaquone selectively inhibits the mitochondrial electron-transport system at the cytochrome bc",
"     <sub>",
"      1",
"     </sub>",
"     complex resulting in depletion of dihydroorotate dehydrogenase and ultimately resulting in the inhibition of nucleic acid and adenosine triphosphate synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;2 years of age: Decreased absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral suspension: Absorption is enhanced 1.4-fold with food; decreased absorption with single doses exceeding 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.6 L/kg; CSF concentration is &lt;1% of the plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Suspension (administered with food): 47%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (4 months to 12 years): 60 hours (range: 31-163 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with AIDS: 2.2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Dual peak serum concentrations at 1 to 8 hours and at 24 to 96 hours after dose due to enterohepatic cycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;94% is recovered as unchanged drug in feces; 0.6% excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The suspension contains the inactive ingredient poloxamer 188",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8501/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,\" June 18, 2008,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4). Available at:",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haile LG and Flaherty JF, &ldquo;Atovaquone: A Review,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(12):1488-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8501/abstract-text/8305784/pubmed\" id=\"8305784\" target=\"_blank\">",
"        8305784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes W, Dorenbaum A, Yogev R, et al, &ldquo;Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone Human Immunodeficiency Virus-Infected Infants and Children. Pediatric AIDS Clinical Trials Group,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1315-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8501/abstract-text/9624466/pubmed\" id=\"9624466\" target=\"_blank\">",
"        9624466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes W, Leoung G, Kramer F, et al, &ldquo;Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Patients With AIDS,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(21):1521-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8501/abstract-text/8479489/pubmed\" id=\"8479489\" target=\"_blank\">",
"        8479489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12856 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8501=[""].join("\n");
var outline_f8_19_8501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045349\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12669219\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045343\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137504\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045352\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045346\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045351\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137555\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045355\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045342\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045341\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298792\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137499\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045358\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137501\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6264005\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045348\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045340\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045354\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045356\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=related_link\">",
"      Atovaquone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/24/16772?source=related_link\">",
"      Atovaquone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8502="Physiologic transition from intrauterine to extrauterine life";
var content_f8_19_8502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiologic transition from intrauterine to extrauterine life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Caraciolo J Fernandes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8502/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/19/8502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The successful transition from intrauterine to extrauterine life is dependent upon significant physiologic changes that occur at birth. In almost all infants, these changes are successfully completed at delivery without requiring any special assistance. However, about 10 percent of infants will need some intervention, and 1 percent will require extensive resuscitative measures at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic changes that occur in the transition from intrauterine to extrauterine life are reviewed here. The indications and principles of neonatal resuscitation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to delivery, the human fetus depends upon the placenta for gas and nutrient exchange with the maternal circulation. A discussion on the development of the placenta, which is essential for normal fetal growth and development, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=see_link\">",
"     \"Placental development and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The low vascular resistance of the placenta and the high vascular resistance of the fluid-filled fetal lungs result in right-to-left shunts characteristic of the fetal circulation (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, the placenta has the lowest vascular resistance and receives 40 percent of the fetal cardiac output, which results in a low systemic pressure (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 1",
"    </a>",
"    ). In contrast, the fetal lungs are filled with fluid, resulting in a high vascular resistance and less than 10 percent of the cardiac output going to the lungs (",
"    <a class=\"graphic graphic_figure graphicRef70458 \" href=\"UTD.htm?10/39/10864\">",
"     figure 2",
"    </a>",
"    ). Two right-to-left shunts occur in the fetus because of the high pulmonary vascular resistance and low systemic pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Foramen ovale &mdash; Blood shunted from the right to left atrium",
"     </li>",
"     <li>",
"      Ductus arteriosus &mdash; Blood shunted from the pulmonary artery to the aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From the placenta, oxygenated blood flows through the umbilical vein and splits upon entering the abdomen of the fetus (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 1",
"    </a>",
"    ). The majority flows through the ductus venosus into the inferior vena cava, and then the right atrium; the remaining blood perfuses the liver. Blood originating from the ductus venosus enters the right atrium and, because of a streaming effect, is largely shunted through the foramen ovale into the left side of the heart and aorta. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Fetal oxygenation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, less oxygenated blood from the superior vena cava and the inferior vena cava distal to the ductus venous flows from the right atrium into the right ventricle with minimal mixing with the oxygenated blood originating from the ductus venosus (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 1",
"    </a>",
"    ). Almost all of the right ventricular output (90 percent) bypasses the lung and is shunted through the patent ductus arteriosus to the descending aorta distal to the origin of the carotid arteries. This deoxygenated blood is transported through the aorta and the umbilical arteries to the placenta, where it releases carbon dioxide and waste products and collects oxygen and nutrients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fetal oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrauterine oxygen tension is low compared to that seen in extrauterine life. The highest oxygenated fetal blood is found in the umbilical vein with PO2 as high as 55 &plusmn; 7 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/2\">",
"     2",
"    </a>",
"    ]. Oxygen saturation decreases when mixed with venous return, so that blood returning to the placenta will have a PO2 of 15 to 25 mmHg.",
"   </p>",
"   <p>",
"    Despite the low oxygen tension in the fetus, there is adequate tissue oxygenation because of the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal hemoglobin &mdash; Fetal hemoglobin has increased oxygen affinity compared to maternal hemoglobin, which facilitates oxygen transport across the placenta. The high affinity of fetal hemoglobin may result in up to 80 percent saturation, a level that promotes sufficient oxygen transport across the placenta to meet the metabolic needs of the fetus.",
"     </li>",
"     <li>",
"      Decreased fetal oxygen consumption &mdash; Intrauterine compared to extrauterine life requires less oxygen because fetal metabolism and oxygen consumption are decreased:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The fetus does not need to maintain thermoregulation because the thermal environment is maintained by the mother.",
"     </li>",
"     <li>",
"      In the fetus, many physiologic functions are reduced, including respiratory effort, gastrointestinal digestion and absorption, and renal tubular reabsorption (due to the low glomerular filtration rate). These changes reduce tissue oxygen consumption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differential blood flow &mdash; In the fetus, the blood flow is structured so that vital organs (eg, liver, heart, and brain) receive blood with a relatively high degree of oxygen saturation (",
"      <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Liver &mdash; The liver receives blood directly from the umbilical vein without mixing with deoxygenated fetal blood.",
"     </li>",
"     <li>",
"      Brain and heart &mdash; Blood flowing through the coronary and carotid arteries has a high degree of oxygen saturation because oxygenated blood from the umbilical vein flows to the right atrium (via the ductus venosus and inferior vena cava) and is shunted through the foramen ovale to the left side of the heart and aorta. This shunting is achieved through differential velocities of incoming venous blood streams and directing of oxygenated blood to the foramen ovale. This reduces mixing of oxygenated blood with deoxygenated blood entering the right atrium from the superior vena cava. The deoxygenated blood is directed toward the right ventricle and shunted through the ductus arteriosus to the aorta but distal to the origin of the carotid and coronary arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low fetal oxygen tension maintains the architecture of the fetal circulation by causing pulmonary vascular constriction, which maintains pulmonary vascular resistance at a high level, thereby promoting right-to-left shunting through the foramen ovale and ductus arteriosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSITION AT DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To successfully make the transition from intrauterine to extrauterine life when the umbilical cord is clamped at birth, the neonate must rapidly make physiologic changes in cardiopulmonary function. A successful transition is characterized by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alveolar fluid clearance",
"     </li>",
"     <li>",
"      Lung expansion",
"     </li>",
"     <li>",
"      Circulatory changes with increases in pulmonary perfusion and systemic pressure, and closure of the right-to-left shunts of the fetal circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alveolar fluid clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms contribute to the clearance of alveolar fluid, including labor, initial breaths, and thoracic squeeze.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labor &mdash; Studies in lamb models have helped elucidate a better understanding of the regulation of alveolar fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/4\">",
"       4",
"      </a>",
"      ]. Chloride-driven liquid secretion predominates during gestation, which stretches the lung and promotes lung growth and development. During late gestation, in response to increased concentrations of catecholamines and other hormones, the lung epithelium switches from active secretion of chloride and liquid into the air spaces to active resorption of sodium and liquid [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Increased oxygen tension at birth enhances the capacity of the epithelium to transport sodium and increases gene expression of the epithelial sodium channel promoting further resorption of alveolar fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial breaths &mdash; The initial effective breaths of the neonate generate high transpulmonary pressures: mean esophageal pressures of -52 cm H2O during inspiration and 71 cmH2O during expiration have been measured in term infants [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/8\">",
"       8",
"      </a>",
"      ]. The initial negative hydrostatic pressure drives alveolar fluid from the air spaces into the interstitium and subsequently the pulmonary vasculature.",
"     </li>",
"     <li>",
"      Thoracic squeeze &mdash; Although once thought to be the primary mechanism for alveolar clearance, the pressure upon the chest wall of the infant during delivery probably is only a minor contributor to alveolar fluid clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lung expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the first effective breath, air movement begins as intrathoracic pressure falls, starting at pressures of less than -5 cm H2O. Increasing inspiratory pressure expands the alveolar air spaces and establishes functional residual capacity (FRC) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/8\">",
"     8",
"    </a>",
"    ]. Lung expansion also stimulates surfactant release, which reduces alveolar surface tension, increases compliance, and stabilizes the FRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Circulatory changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the clamping of the umbilical cord, the placenta with its low vascular resistance is removed from the neonatal circulation, resulting in a rise in neonatal systemic blood pressure. At the same time, lung expansion reduces both pulmonary vascular resistance and the pulmonary artery pressure.",
"   </p>",
"   <p>",
"    These two changes decrease the right-to-left shunt at the ductus arteriosus, resulting in an increased blood flow through the pulmonary arteries and lungs. With increased lung perfusion and expansion, neonatal oxygenation saturation is increased, which stimulates closure of the ductus arteriosus.",
"   </p>",
"   <p>",
"    In addition, the increased pulmonary arterial blood flow raises pulmonary venous return to the left atrium and left atrial pressure. As the left atrial pressure increases and the right atrial pressure falls, right-to-left shunting across the foramen ovale decreases. Closure of the foramen ovale occurs when the left atrial pressure exceeds the right atrial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFICULTIES IN TRANSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most neonates successfully transition between intrauterine and extrauterine life, about 10 percent will have some difficulty and require resuscitative efforts at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following risk factors are associated with a greater likelihood of having difficulty making a successful transition and of requiring resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal conditions &mdash; Advanced maternal age, maternal diabetes mellitus or hypertension, maternal substance abuse, or previous history of stillbirth, fetal loss or early neonatal death",
"     </li>",
"     <li>",
"      Fetal conditions &mdash; Prematurity, postmaturity, congenital anomalies, or multiple gestation",
"     </li>",
"     <li>",
"      Antepartum complications &mdash; Placental anomalies (eg, placenta previa), or either oligohydramnios or polyhydramnios",
"     </li>",
"     <li>",
"      Delivery complications &mdash; Transverse lie or breech presentation, chorioamnionitis, foul-smelling or meconium-stained amniotic fluid, antenatal asphyxia with abnormal fetal heart rate pattern, maternal administration of a narcotic within four hours of birth, or delivery that requires instrumentation (eg, forceps, vacuum, or cesarean delivery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal difficulties at birth include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of respiratory effort",
"     </li>",
"     <li>",
"      Blockage of the airways",
"     </li>",
"     <li>",
"      Impaired lung function",
"     </li>",
"     <li>",
"      Persistent increased pulmonary vascular resistance (also referred to as persistent pulmonary hypertension or persistent fetal circulation)",
"     </li>",
"     <li>",
"      Abnormal cardiac structure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lack of respiratory effort",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of vigorous, regular spontaneous respirations at birth interferes with alveolar fluid clearance, lung inflation, and reduction of pulmonary vascular resistance. Poor or absent spontaneous respiratory effort suggests that the infant is neurologically depressed (usually brain asphyxia) or has impaired muscular function. Causes of impaired respiratory effort vary from benign and readily reversible problems (eg, exposure to maternally administered opioids) to more severe and refractory problems (eg, severe and prolonged hypoxia or congenital neuromuscular disorder). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Blockage of the airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical blockage of the airway prevents the infant from making adequate initial breaths, thereby interfering with alveolar fluid clearance, lung inflation, and the fall in pulmonary vascular resistance. Causes of blockage include congenital airway malformation (eg, bilateral choanal atresia or Robin sequence syndrome); the presence of meconium or mucus in the airway; or rarely, airway obstruction due to disorders such as laryngeal webs, cystic hygroma, or congenital goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8502/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Robin sequence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Airway obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Impaired lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions can impair lung function, resulting in respiratory distress of the neonate at delivery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      External causes &mdash; Any collection between the lung and the chest wall will prevent the lung from expanding. This includes pneumothorax and pleural effusions, which may occur in an infant with hydrops fetalis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=see_link&amp;anchor=H5#H5\">",
"       \"Pulmonary air leak in the newborn\", section on 'Pneumothorax'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"       \"Nonimmune hydrops fetalis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hypoplasia &mdash; In congenital diaphragmatic hernia, pulmonary hypoplasia occurs because of external compression of the fetal lung by the herniated abdominal contents. Pulmonary hypoplasia also is associated with oligohydramnios and is seen in infants with severe congenital anomalies of the kidney and urinary tract. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link\">",
"       \"Congenital diaphragmatic hernia in the neonate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Amniotic fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intrinsic lung disease &mdash; In preterm infants, impaired lung function is due to deficient pulmonary surfactant, leading to hyaline membrane disease, or antenatally acquired pneumonia. In fullterm infants, causes include transient tachypnea of the newborn, which results from delayed resorption and clearance of fetal lung fluid, and antenatally acquired pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"       \"Transient tachypnea of the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of respiratory distress at birth are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Persistent pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;If adequate ventilation does not occur immediately after birth because of apnea, airway blockage, or impaired lung function, hypoxia and acidosis develop, leading to persistence of pulmonary vasoconstriction and pulmonary hypertension. Persistent pulmonary hypertension causes persistent right-to-left shunting through the ductus arteriosus and foramen ovale, resulting in decreased pulmonary arterial flow and continued hypoxemia and hypercapnia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with severe congenital heart disease may have difficulty with the transition to extrauterine life, especially those infants with cyanotic heart disease who are dependent upon a patent ductus arteriosus for pulmonary or systemic blood flow, or those with severe pulmonary edema due to increased pulmonary arterial blood flow or impaired left ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H270523701#H270523701\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Critical CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The successful transition from intrauterine to extrauterine life is dependent upon significant physiologic changes that occur at birth. In almost all infants (90 percent), these changes are successfully completed at delivery without requiring any special assistance.",
"     </li>",
"     <li>",
"      When the umbilical cord is clamped, an uneventful transition to extrauterine life includes successful alveolar fluid clearance, lung expansion, and conversion from fetal to newborn circulation with increased pulmonary arterial blood flow, increased systemic pressure, and closure of the right-to-left shunts (foramen ovale and ductus arteriosus) of the fetal circulation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transition at delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 10 percent neonates have some difficulty and require resuscitative efforts at birth. Infants who are more likely to require resuscitation can be identified by maternal and neonatal risk factors, and the presence of antepartum and delivery room complications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Difficulties in transition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A more difficult transition at birth may be due to the lack of respiratory effort of the infant, blockage of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      airway, impaired neonatal lung function, persistent increased pulmonary vascular resistance, or the presence of cardiac disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Difficulties in transition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/1\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al. Part 15: neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/2\">",
"      Soothill PW, Nicolaides KH, Rodeck CH, Gamsu H. Blood gases and acid-base status of the human second-trimester fetus. Obstet Gynecol 1986; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     Goldsmith JP. Delivery room resuscitation of the newborn. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 1, p.449.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/4\">",
"      Olver RE, Walters DV, M Wilson S. Developmental regulation of lung liquid transport. Annu Rev Physiol 2004; 66:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/5\">",
"      Bland RD, Nielson DW. Developmental changes in lung epithelial ion transport and liquid movement. Annu Rev Physiol 1992; 54:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/6\">",
"      O'Brodovich HM. Immature epithelial Na+ channel expression is one of the pathogenetic mechanisms leading to human neonatal respiratory distress syndrome. Proc Assoc Am Physicians 1996; 108:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/7\">",
"      Wilson SM, Olver RE, Walters DV. Developmental regulation of lumenal lung fluid and electrolyte transport. Respir Physiol Neurobiol 2007; 159:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8502/abstract/8\">",
"      Vyas H, Field D, Milner AD, Hopkin IE. Determinants of the first inspiratory volume and functional residual capacity at birth. Pediatr Pulmonol 1986; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Overview and principles of resuscitation. In: Textbook of Neonatal Resuscitation, 5th ed, Kattwinkel, J (Ed), American Academy of Pediatrics 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4970 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8502=[""].join("\n");
var outline_f8_19_8502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fetal oxygenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSITION AT DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alveolar fluid clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lung expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Circulatory changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFICULTIES IN TRANSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lack of respiratory effort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Blockage of the airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Impaired lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Persistent pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4970|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15032\" title=\"figure 1\">",
"      Fetal circulation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/39/10864\" title=\"figure 2\">",
"      Fetal cardiac output distributi",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8503="Serous cystadenoma Gross";
var content_f8_19_8503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gross appearance of pancreatic serous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross appearance of pancreatic serous cystadenoma. Note central stellate scar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L Steer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8503=[""].join("\n");
var outline_f8_19_8503=null;
var title_f8_19_8504="Familial polyposis Endosc";
var content_f8_19_8504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearance of multiple polyps in familial adenomatous polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic findings at multiple levels in a 50-year-old man with familial adenomatous polyposis. Multiple polyps of various sizes are seen. At colectomy, some of these polyps had areas of high-grade dysplasia and early malignant transformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8504=[""].join("\n");
var outline_f8_19_8504=null;
var title_f8_19_8505="Enalapril: Drug information";
var content_f8_19_8505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enalapril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30197?source=see_link\">",
"    see \"Enalapril: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"    see \"Enalapril: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Enalapril&reg;;",
"     </li>",
"     <li>",
"      CO Enalapril;",
"     </li>",
"     <li>",
"      Mylan-Enalapril;",
"     </li>",
"     <li>",
"      Novo-Enalapril;",
"     </li>",
"     <li>",
"      PMS-Enalapril;",
"     </li>",
"     <li>",
"      PRO-Enalapril;",
"     </li>",
"     <li>",
"      RAN&trade;-Enalapril;",
"     </li>",
"     <li>",
"      ratio-Enalapril;",
"     </li>",
"     <li>",
"      Riva-Enalapril;",
"     </li>",
"     <li>",
"      Sandoz-Enalapril;",
"     </li>",
"     <li>",
"      Sig-Enalapril;",
"     </li>",
"     <li>",
"      Taro-Enalapril;",
"     </li>",
"     <li>",
"      Teva-Enalapril;",
"     </li>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe congestive heart failure, decreased renal function, or in those receiving diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asymptomatic left ventricular dysfunction:",
"     </b>",
"     Oral: 2.5 mg twice daily, titrated as tolerated to 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 2.5 mg once or twice daily (usual range: 5-40 mg/day in 2 divided doses); titrate slowly at 1- to 2-week intervals. Target dose: 10-20 mg twice daily (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-5 mg/day then increase as required, usually at 1- to 2-week intervals; usual dose range (JNC 7): 2.5-40 mg/day in 1-2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Initiate with 2.5 mg if patient is taking a diuretic which cannot be discontinued. May add a diuretic if blood pressure cannot be controlled with enalapril alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Conversion from I.V.",
"     <b>",
"      enalaprilat",
"     </b>",
"     to oral",
"     <b>",
"      enalapril",
"     </b>",
"     therapy: If not concurrently receiving diuretics, initiate enalapril 5 mg once daily; if concurrently receiving diuretics and responding to enalaprilat 0.625 mg I.V. every 6 hours, initiate with enalapril 2.5 mg once daily; subsequent titration as needed.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F164779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"      see \"Enalapril: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Children 1 month to 17 years: Oral: Initial: 0.08 mg/kg/day (up to 5 mg) in 1-2 divided doses; adjust dosage based on patient response; doses &gt;0.58 mg/kg (40 mg) have not been evaluated in pediatric patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure (unlabeled dosing):",
"     </b>",
"     Infants and Children: Oral: Initial: 0.1 mg/kg/day in 1-2 divided doses; increase as required over 2 weeks to maximum of 0.5 mg/kg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Mean dose required for CHF improvement in 39 children (9 days to 17 years) was 0.36 mg/kg/day; select individuals have been treated with doses up to 0.94 mg/kg/day (Leversha, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in infants and children &le;16 years of age with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     is not recommended (no dosing data exists).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Administer 2.5 mg day; titrated upward until blood pressure is controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heart failure patients with sodium &lt;130 mEq/L or serum creatinine &gt;1.6 mg/dL: Initiate dosage with 2.5 mg/day, increasing to twice daily as needed. Increase further in increments of 2.5 mg/dose at &gt;4-day intervals to a maximum daily dose of 40 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): Moderately dialyzable (20% to 50%): Initial: 2.5 mg on dialysis days; adjust dose on nondialysis days depending on blood pressure response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from I.V.",
"     <b>",
"      enalaprilat",
"     </b>",
"     to oral",
"     <b>",
"      enalapril",
"     </b>",
"     therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: May initiate enalapril 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: May initiate enalapril 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75-100% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary, although some removal of drug occurs.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F164759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrolysis of enalapril to enalaprilat may be delayed and/or impaired in patients with severe hepatic impairment, but the pharmacodynamic effects of the drug do not appear to be significantly altered. No dosage adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 2.5 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vasotec&reg;: 2.5 mg, 5 mg, 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; treatment of symptomatic heart failure; treatment of asymptomatic left ventricular dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F164800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     To delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus; hypertensive crisis, diabetic nephropathy, hypertension secondary to scleroderma renal crisis, diagnosis of aldosteronism, idiopathic edema, Bartter's syndrome, postmyocardial infarction for prevention of ventricular failure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F164813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enalapril may be confused with Anafranil&reg;, Elavil&reg;, Eldepryl&reg;, ramipril",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril [Hungary, Switzerland] may be confused with Accupril which is a brand name for quinapril [U.S., Canada, multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril: Brand name for enalapril [Hungary, Switzerland], but also brand name for captopril [Great Britain]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with CHF. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 7%), chest pain (2%), syncope (&le;2%), orthostasis (2%), orthostatic hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 5%), dizziness (4% to 8%), fatigue (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste, abdominal pain, vomiting, nausea, diarrhea, anorexia, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (&le;20%), worsening of renal function (in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory (1% to 2%): Bronchitis, cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, anaphylactoid reaction, angina pectoris, angioedema, ataxia, atrial fibrillation, atrial tachycardia, bone marrow suppression, bradycardia, cardiac arrest, cerebral vascular accident, cholestatic jaundice, depression, eosinophilia, eosinophilic pneumonitis, erythema multiforme, erythrocyte sedimentation rate increased, exfoliative dermatitis, giant cell arteritis, gynecomastia, hallucinations, hemolysis with G6PD, Henoch-Sch&ouml;nlein purpura, hepatitis, ileus, interstitial nephritis, lichen-form reaction, melena, MI, neutropenia, ototoxicity, pancreatitis, pemphigus, pemphigus foliaceus, peripheral neuropathy, photosensitivity, positive ANA, psychosis, pulmonary edema, pulmonary embolism, pulmonary infiltrates, Raynaud&rsquo;s phenomenon, sicca syndrome, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia, toxic epidermal necrolysis, toxic pustuloderma, vasculitis, visual hallucinations (Doane, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enalapril or enalaprilat; angioedema related to previous treatment with an ACE inhibitor; patients with idiopathic or hereditary angioedema; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F164746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of enalapril (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Enalaprilat, the active metabolite of enalapril, crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6197985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enalapril and enalaprilat are excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F164733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit salt substitutes or potassium-rich diet.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Enalapril Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $80.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $102.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $107.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $152.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vasotec Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $90.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $341.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $375.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $164.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acebitor (PH);",
"     </li>",
"     <li>",
"      Acetec (MY);",
"     </li>",
"     <li>",
"      Acetensil (ES);",
"     </li>",
"     <li>",
"      Alapren (ZA);",
"     </li>",
"     <li>",
"      Alphapril (AU);",
"     </li>",
"     <li>",
"      Amprace (AU, NZ);",
"     </li>",
"     <li>",
"      Analept (GR);",
"     </li>",
"     <li>",
"      Anapril (SG);",
"     </li>",
"     <li>",
"      Antens (KP);",
"     </li>",
"     <li>",
"      Auspril (AU);",
"     </li>",
"     <li>",
"      Bajaten (CN);",
"     </li>",
"     <li>",
"      Beartec (KP);",
"     </li>",
"     <li>",
"      Benalipril (DE);",
"     </li>",
"     <li>",
"      Berlipril (BG);",
"     </li>",
"     <li>",
"      Biocronil (CO);",
"     </li>",
"     <li>",
"      BQL (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Co-Renitec (CY);",
"     </li>",
"     <li>",
"      Converten (IN);",
"     </li>",
"     <li>",
"      Convertin (IL);",
"     </li>",
"     <li>",
"      Corodil (DK);",
"     </li>",
"     <li>",
"      Corvo (CR, PA);",
"     </li>",
"     <li>",
"      Danssan (MY);",
"     </li>",
"     <li>",
"      Ecaprinil (CR, PA);",
"     </li>",
"     <li>",
"      Ednyt (BB, BM, BS, BZ, GY, HU, JM, SR, TT);",
"     </li>",
"     <li>",
"      Elfonal (KP);",
"     </li>",
"     <li>",
"      Enace (TH);",
"     </li>",
"     <li>",
"      Enahexal (AU, NZ);",
"     </li>",
"     <li>",
"      Enalabell (AU);",
"     </li>",
"     <li>",
"      Enalagamma (DE);",
"     </li>",
"     <li>",
"      Enalapril (ES);",
"     </li>",
"     <li>",
"      Enaloc (FI);",
"     </li>",
"     <li>",
"      Enap (HK, HR, HU, SG);",
"     </li>",
"     <li>",
"      Enap i.v. (HR);",
"     </li>",
"     <li>",
"      Enap [inj.] (HU);",
"     </li>",
"     <li>",
"      Enapren (IT);",
"     </li>",
"     <li>",
"      Enaprin (KP);",
"     </li>",
"     <li>",
"      Enaril (KP, TH);",
"     </li>",
"     <li>",
"      Enatec (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Enazil (PL);",
"     </li>",
"     <li>",
"      Enbid-20 (PH);",
"     </li>",
"     <li>",
"      Enetil (CO);",
"     </li>",
"     <li>",
"      Enpril (KP);",
"     </li>",
"     <li>",
"      Envas (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Glioten (BR, EC, PE, PY, SG);",
"     </li>",
"     <li>",
"      Grifopril (CN);",
"     </li>",
"     <li>",
"      Hypace (PH);",
"     </li>",
"     <li>",
"      Hyperil (KP);",
"     </li>",
"     <li>",
"      Hypril (PH);",
"     </li>",
"     <li>",
"      Hytrol (IN);",
"     </li>",
"     <li>",
"      Ileveran (MX);",
"     </li>",
"     <li>",
"      Innovace (GB, IE);",
"     </li>",
"     <li>",
"      Invoril (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Korandil (CY);",
"     </li>",
"     <li>",
"      Lapril (TH);",
"     </li>",
"     <li>",
"      Lenipril (KP);",
"     </li>",
"     <li>",
"      Lotrial (AR, PE, UY);",
"     </li>",
"     <li>",
"      Meipril (ID);",
"     </li>",
"     <li>",
"      Naprilate (PH);",
"     </li>",
"     <li>",
"      Naprilene (IT);",
"     </li>",
"     <li>",
"      Narapril (KP);",
"     </li>",
"     <li>",
"      Naritec (TH);",
"     </li>",
"     <li>",
"      Neopril (KP);",
"     </li>",
"     <li>",
"      Nor-Prilat (DO, GT, NI, SV);",
"     </li>",
"     <li>",
"      Nuril (IN);",
"     </li>",
"     <li>",
"      Olivin (HR);",
"     </li>",
"     <li>",
"      Pharmapress (HK);",
"     </li>",
"     <li>",
"      Pres (DE);",
"     </li>",
"     <li>",
"      Presil (CO);",
"     </li>",
"     <li>",
"      Prilace (EC);",
"     </li>",
"     <li>",
"      Rapril (KP);",
"     </li>",
"     <li>",
"      Renallapin (KP);",
"     </li>",
"     <li>",
"      Renitec (AR, AT, AU, BE, BF, BG, BJ, BR, CI, CL, CO, CZ, EE, EG, ES, ET, FI, FR, GH, GM, GN, GR, HK, HN, HU, KE, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PT, SC, SD, SE, SL, SN, TH, TN, TR, TW, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Renitek (RU);",
"     </li>",
"     <li>",
"      Reniten (CH);",
"     </li>",
"     <li>",
"      Renivace (JP);",
"     </li>",
"     <li>",
"      Tenace (ID);",
"     </li>",
"     <li>",
"      Tenaten (ID);",
"     </li>",
"     <li>",
"      Unaril (TW);",
"     </li>",
"     <li>",
"      Unipril (CO);",
"     </li>",
"     <li>",
"      Vasopress (PH);",
"     </li>",
"     <li>",
"      Xanef (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 55% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50% (Davies, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug, undergoes hepatic biotransformation to enalaprilat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enalapril: Adults: Healthy: 2 hours; Congestive heart failure: 3.4-5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enalaprilat: Infants 6 weeks to 8 months of age: 6-10 hours (Lloyd, 1989); Adults: ~35 hours (Till, 1984; Ulm, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Enalapril: 0.5-1.5 hours; Enalaprilat (active metabolite): 3-4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (61%; 18% of which was enalapril, 43% was enalaprilat); feces (33%; 6% of which was enalapril, 27% was enalaprilat) (Ulm, 1982)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Bellissant E, Pussard E, et al, &ldquo;Placebo-Controlled, Randomized, Double-Blind Study of Intravenous Enalaprilat Efficacy and Safety in Acute Cardiogenic Pulmonary Edema,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 94(6):1316-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/8822986/pubmed\" id=\"8822986\" target=\"_blank\">",
"        8822986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies RO, Gomez HJ, Irvin JD, et al, \"An Overview of the Clinical Pharmacology of Enalapril,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1984, 18(Suppl 2):215-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/6099737/pubmed\" id=\"6099737\" target=\"_blank\">",
"        6099737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013 [epub ahead pf print].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leversha AM, Wilson NJ, Clarkson PM, et al, &ldquo;Efficacy and Dosage of Enalapril in Congenital and Acquired Heart Disease,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(1):35-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/8110005/pubmed\" id=\"8110005\" target=\"_blank\">",
"        8110005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd TR, Mahoney LT, Knoedel D, et al, &ldquo;Orally Administered Enalapril for Infants With Congestive Heart Failure: A Dose-Finding Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4):650-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/2538615/pubmed\" id=\"2538615\" target=\"_blank\">",
"        2538615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakamura H, Ishii M, Sugimura T, et al, &ldquo;The Kinetic Profiles of Enalapril and Enalaprilat and Their Possible Developmental Changes in Pediatric Patients With Congestive Heart Failure,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(2):160-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/8062492/pubmed\" id=\"8062492\" target=\"_blank\">",
"        8062492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Till AE, Gomez HJ, Hichens M, et al, \"Pharmacokinetics of Repeated Single Oral Doses of Enalapril Maleate (MK-421) in Normal Volunteers,\"",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1984, 5(3):273-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/6091806/pubmed\" id=\"6091806\" target=\"_blank\">",
"        6091806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulm EH, Hichens M, Gomez HJ, et al, \"Enalapril Maleate and a Lysine Analogue (MK-521): Disposition in Man,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1982, 14(3):357-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/6289858/pubmed\" id=\"6289858\" target=\"_blank\">",
"        6289858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/19/8505/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9405 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8505=[""].join("\n");
var outline_f8_19_8505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708730\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164804\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164756\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164779\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164757\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164758\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164759\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164704\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164723\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164800\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164813\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164802\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164728\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164708\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164713\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164746\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164716\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164731\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164763\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6197985\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164733\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164730\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164718\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164734\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164707\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164727\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30197?source=related_link\">",
"      Enalapril: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=related_link\">",
"      Enalapril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8506="Pathophysiology and clinical features of isolated ventricular septal defects in infants and children";
var content_f8_19_8506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Kirsten Bourke Dummer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8506/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8506/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/19/8506/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/19/8506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common congenital heart lesion is ventricular septal defect (VSD). It occurs in almost 50 percent of all patients with congenital heart disease with a reported prevalence of 41.8 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/1\">",
"     1",
"    </a>",
"    ]. VSDs occur in isolation or in combination with other congenital heart defects, as in an atrioventricular canal (AVC), tetralogy of Fallot (TOF) and occasionally, transposition of the great arteries (D-TGA). These complex defects are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology, natural history, clinical manifestations, and evaluation of isolated VSDs in children will be presented here. The echocardiographic evaluation and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=see_link\">",
"     \"Echocardiographic evaluation of ventricular septal defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"     \"Management of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main anatomic components of the interventricular septum (",
"    <a class=\"graphic graphic_figure graphicRef51288 \" href=\"UTD.htm?8/14/8419\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60615 \" href=\"UTD.htm?41/7/42096\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Component 1: The septum of the atrioventricular (AV) canal",
"     </li>",
"     <li>",
"      Component 2: The muscular septum",
"     </li>",
"     <li>",
"      Component 3: The parietal band or distal conal septum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Embryologically, closure of the interventricular foramen is dependent upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Projections into the atrioventricular canal from the right-sided endocardial cushions (component 1)",
"     </li>",
"     <li>",
"      Continued growth of connective tissue on the crest of the muscular septum (component 2)",
"     </li>",
"     <li>",
"      Downward growth of ridges dividing the conus (component 3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VSDs may occur at various locations in any of the three components. The particular location of the defect has no bearing on the characteristics of the intracardiac shunt, but is important in terms of the frequency of involvement of the semilunar valves or atrioventricular valvar attachments, and the likelihood of spontaneous closure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, the relationship of the defect to the AV conduction pathway is an important aspect of surgical repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of isolated ventricular septal defects in infants and children\", section on 'Surgical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Membranous defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors are involved in embryologic closure of the region encompassing the membranous septum. Thus, it is not surprising that this is the most common site of VSDs; 75 percent of VSDs are membranous (component 3 with extension to component 2) (",
"    <a class=\"graphic graphic_figure graphicRef51288 \" href=\"UTD.htm?8/14/8419\">",
"     figure 1",
"    </a>",
"    ). Defects in this region also are called perimembranous, conoventricular, or subaortic.",
"   </p>",
"   <p>",
"    Membranous VSDs lie just beneath the aortic valve and behind the septal leaflet of the tricuspid valve. Often these defects have extension into the inlet or muscular septum, and can undergo partial or complete closure by apposition of the septal leaflet of the tricuspid valve, forming a tricuspid valve \"pouch\" or \"aneurysm of the ventricular septum\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Less commonly, they can be closed by prolapse of an aortic cusp into the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/10\">",
"     10",
"    </a>",
"    ]. Occasionally, these defects can be associated with left ventricular outflow tract obstruction and coarctation of the aorta. Because the bundle of His lies in a subendocardial position and courses along the posterior-inferior margin of the defect, heart block is a potential surgical complication [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some anatomists define malalignment defects, those resulting from anterior or posterior malalignment of the conal septum, as separate from membranous defects, although the anatomic location can be identical. Anterior malalignment defects occur in TOF, whereas posterior malalignment defects cause left ventricular outflow tract obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Subpulmonic (outlet)",
"    </span>",
"    &nbsp;&mdash;&nbsp;VSDs that are superior and anterior in location are referred to as subpulmonic or outlet defects (also called supracristal, infundibular, conal septal, or doubly committed subarterial defects), confined to component 3 (",
"    <a class=\"graphic graphic_figure graphicRef51288 \" href=\"UTD.htm?8/14/8419\">",
"     figure 1",
"    </a>",
"    ). These defects account for approximately 5 percent of defects in North America and western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/12\">",
"     12",
"    </a>",
"    ], but are more common (approximately 30 percent) in the Asian population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/13\">",
"     13",
"    </a>",
"    ]. Subpulmonic defects are located immediately beneath the valves of both arterial trunks. They commonly are associated with prolapse of the right coronary cusp of the aortic valve with or without aortic regurgitation. Outlet defects rarely close spontaneously. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Aortic regurgitation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"     \"Management of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AV canal (inlet)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of VSDs are inlet or AV canal-type defects. These defects occur posterior and superior between the annulus of the tricuspid valve and the attachments of the tricuspid valve to the right ventricular wall and septum (component 1) (",
"    <a class=\"graphic graphic_figure graphicRef51288 \" href=\"UTD.htm?8/14/8419\">",
"     figure 1",
"    </a>",
"    ). Inlet defects are seldom isolated, more commonly associated with an atrial septal defect as part of a complete AV-canal or endocardial cushion defect. They do not close spontaneously.",
"   </p>",
"   <p>",
"    Inlet defects occupy the area of septum inferior to the normal conduction tissue axis. This causes inferior deviation of the AV node and bundle of His, which results in abnormal QRS axis on electrocardiogram (ECG) and vulnerability to AV block, both spontaneous and surgically-induced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscular defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 15 percent of VSDs are muscular defects, located along the right ventricular free wall-septal junction (marginal muscular defects), central, or in the apical septum (component 2) (",
"    <a class=\"graphic graphic_figure graphicRef51288 \" href=\"UTD.htm?8/14/8419\">",
"     figure 1",
"    </a>",
"    ). Small muscular defects are even more common in very premature infants. Muscular defects often close spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/14\">",
"     14",
"    </a>",
"    ]. Midventricular muscular VSDs more often close spontaneously and earlier than other muscular types of VSDs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Multiple defects, referred to as \"Swiss cheese\" septum, are present occasionally and have the same net functional effect as a single large defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/16\">",
"     16",
"    </a>",
"    ]. Apical defects can be difficult to visualize on the right ventricular (RV) side because they may be covered by thick trabeculations of the right ventricle, making right-sided surgical repair difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a VSD in utero has little effect on the normal cardiac physiology. The RV output preferentially flows through the ductus arteriosus to the descending aorta to supply the abdominal viscera, lower extremities and the placenta with minimal flow to the high resistance pulmonary bed. Simultaneously, left ventricular output supplies flow to the head and neck with a small percentage of flow crossing the distal aortic arch. Thus, each ventricle generates equivalent systolic pressure.",
"   </p>",
"   <p>",
"    In the presence of a large VSD, shunting is dependent on the relative resistance to flow during systole. In utero, the resistances downstream from each ventricle are equal. Thus, there is minimal shunting of blood despite a large ventricular communication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of left to right shunts\", section on 'Fetal and transitional circulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the infant is delivered, the low resistance placenta is removed from the circulation and the ductus arteriosus closes. In addition, there is an immediate fall in pulmonary vascular resistance (PVR), with a continued, more gradual decline that may extend over weeks to months. As a result, after birth, the LV contracts against high systemic vascular resistance, while the RV contracts against the lower resistance pulmonary circulation. This difference in the resistance of the two vascular beds results in a left-to-right shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Size of defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic effects of VSDs depend upon the size of the defect and the PVR. These variables change with time and the clinical manifestations may change accordingly. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natural history'",
"    </a>",
"    below.) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/16\">",
"     16",
"    </a>",
"    ]. The pathophysiology of VSDs is summarized briefly below and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathophysiology of left to right shunts\", section on 'Ventricular level shunts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small defects (also called restrictive defects) with high resistance to flow permit only a small left-to-right shunt (usually &lt;50 percent of ventricular output). Right ventricle (RV) pressure remains normal or only minimally elevated; pulmonary artery pressures and PVR are normal and there is little increase in ventricular stroke work.",
"     </li>",
"     <li>",
"      Moderate defects (moderately restrictive defects) offer resistance to pressure but usually little resistance to flow. The RV pressure, PVR, and pulmonary artery pressures may remain low or be moderately elevated. The magnitude of the left-to-right shunt depends primarily upon the size of the defect. This can result in volume overload of the left atrium and ventricle, and signs and symptoms of heart failure. Pulmonary pressure usually remains normal or only mildly elevated because of the restrictive nature of the defect and the resultant large pressure gradient from left to right ventricle.",
"     </li>",
"     <li>",
"      Large defects (equal to or greater in size than the cross-sectional diameter of the aortic root) offer little resistance to flow; they are sometimes called \"unrestrictive defects.\" The pressure in the ventricles is equal and they function as a common pumping chamber with two outlets. The magnitude of the left-to-right shunt depends upon relative pulmonary and systemic vascular resistance. As PVR declines, there is a large left-to-right shunt that generates increased pulmonary blood flow, increased pulmonary venous return, and increased volume load to the LV. This left ventricular volume overload may result in LV hypertrophy (LVH) and increased end-diastolic pressure, which in turn may cause increased pulmonary venous pressure and worsen symptoms of heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Changes in PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, PVR declines gradually over the first several weeks of life. It declines more rapidly in premature infants. In infants with moderate or large VSDs the decline in PVR may be delayed for several months. The rate of decline of PVR also is delayed by a number of other factors, including the development of pulmonary edema and altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effects on pulmonary circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased pulmonary blood flow may result in increased ventilatory effort, primarily tachypnea, but also dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. Over time, increased pulmonary blood flow can result in increased pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effects on systemic circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with VSD who are shunting blood from the systemic to the pulmonic circulation, LV output must increase to maintain systemic blood flow at normal levels. The increase in LV output depends upon the size of the shunt, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      25 percent shunt requires a 1.33-fold increase in LV output",
"     </li>",
"     <li>",
"      50 percent shunt requires a 2-fold increase in LV output",
"     </li>",
"     <li>",
"      75 percent shunt requires a 4-fold increase in LV output",
"     </li>",
"     <li>",
"      80 percent shunt requires a 5-fold increase in LV output",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By convention, the magnitude of left-to-right shunting is designated by using the ratio of pulmonary to systemic blood flow (Qp:Qs). Thus, Qp:Qs for a 25 percent shunt is 1.33:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. As shunt volumes increase above approximately 60 percent, small increases in shunt volume must be accompanied by dramatic increases in LV output to maintain systemic circulation at normal levels. When the LV is no longer able to maintain such increased output demands, systemic blood flow falls and high output failure ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors can increase the demand for systemic blood flow in infants and children with VSD. These include cooling, sympathetic stimulation, increased respiratory effort, anxiety, and decreased hemoglobin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As systemic output decreases, several mechanisms act to increase systemic vascular resistance. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased alpha-adrenergic stimulation by sympathetic nerves (due to distension of the cardiac chambers and from baroreflex stimulation as cardiac output is reduced and arterial pressure falls)",
"     </li>",
"     <li>",
"      Increased circulating catecholamine concentrations",
"     </li>",
"     <li>",
"      Increased angiotensin II and vasopressin concentrations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These responses may exacerbate cardiac failure, and contribute to the clinical manifestations. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated VSDs is related to the size of the defect as illustrated below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Small VSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seventy-five percent of small defects undergo spontaneous closure within the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. Defects located in the muscular septum close with the growth and hypertrophy of the surrounding muscular septum. Small membranous defects also may close through apposition of the septal leaflet of the tricuspid valve secondary to negative pressure created by the jet through the defect. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Membranous defects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Small VSDs that persist into adulthood are usually benign. The Second Joint Study on Natural History of Congenital Heart Defects provided comprehensive data on 242 young adults known to have a small VSD who were medically managed and followed from early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/17\">",
"     17",
"    </a>",
"    ]. Spontaneous closure occurred in 13.6 percent, but most of the patients were older than two years on admission into the study and had passed through the time when spontaneous closure is most common. Bacterial endocarditis occurred in nine patients (12.8 per 10,000 person-years of follow-up). In the entire cohort of 570 with VSDs of all sizes, 12 patients (2 percent) developed aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another review, adult patients with a VSD considered too small to require surgery during childhood were followed to a mean age of 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/18\">",
"     18",
"    </a>",
"    ]. There were no deaths; spontaneous closure occurred in 6 percent, and endocarditis in 1.4 percent. At last visit, 95 percent were symptom-free, left ventricular size was increased in only one, no patient had left ventricular dysfunction, and mean exercise capacity was 92 percent of predicted. Features predictive of a benign course included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A left-to-right shunt less than 33 percent",
"      <span class=\"nowrap\">",
"       (Qp/Qs",
"      </span>",
"      &lt;1.5)",
"     </li>",
"     <li>",
"      No evidence of left ventricular volume overload",
"     </li>",
"     <li>",
"      Normal pulmonary artery pressure",
"     </li>",
"     <li>",
"      No VSD-related aortic regurgitation or symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of patients referred to a national cardiac center in the United Kingdom, the following findings were noted among 188 patients with a small VSD, age 17 to 72 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An additional cardiac lesion, most commonly a bicuspid aortic valve or coarctation of the aorta, was present in 27 percent.",
"     </li>",
"     <li>",
"      During a 13 year follow up, 47 percent of patients remained stable and had no complications, and 10 percent had spontaneous closure during adulthood (0.8 percent per year).",
"     </li>",
"     <li>",
"      Serious complications occurred in 25 percent, including infective endocarditis in 11 percent, progressive aortic regurgitation requiring surgery in 5 percent, and age-related symptomatic arrhythmias, primarily atrial fibrillation, in 8.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher rate of complications in this study compared to The Second Joint Study on Natural History of Congenital Heart Defects may be due to referral bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Moderate VSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of moderate size VSDs varies depending upon pulmonary arterial pressure, and the size and location of the defect. The size of the defect may diminish over time and spontaneous closure may occur, although less frequently than with small VSDs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Less commonly than spontaneous closure, patients with a membranous VSD may develop acquired obstruction to the right ventricle (RV) outflow tract (also referred to as double chambered right ventricle) that reduces volume overload in the left ventricle (LV) and protects the pulmonary vascular bed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'RV outflow obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Depending upon RV and pulmonary arterial (PA) pressures, children with moderate VSDs and a persistent left-to-right shunt may remain hemodynamically and clinically stable or improve for several years despite increased left atrial and ventricular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. This was illustrated in a long-term follow-up study (mean time of follow-up 7.8 years) of 33 unoperated children with moderate sized, restrictive VSD with severe LV dilation but no evidence of cardiac failure or pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/23\">",
"     23",
"    </a>",
"    ]. At follow-up, these patients had a spontaneous reduction in LV dilation measured by echocardiography (decrease of mean LV end diastolic dimension z score from 3 to 1.2) suggesting lower LV volumes due to reduced left-to-right shunt.",
"   </p>",
"   <p>",
"    When PA and RV pressures are &lt;50 percent of systemic arterial systolic pressures, the left-to-right shunt may be moderate or large, and cardiac failure may result, although it is usually easily controlled with medications and PVR usually does not increase. As a result surgical or catheter-based intervention is not required. &nbsp;The risk of development of irreversible pulmonary vascular obstructive disease increases when pulmonary arterial pressures are greater than 50 percent of systemic pressures, which requires closure of the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"     \"Management of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Large VSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large VSDs rarely close spontaneously. Infants with these defects usually develop large left-to-right shunts in the first few weeks of life, resulting in signs of pulmonary overcirculation and failure to thrive. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unless surgery is performed in the first year of life, there is increasing likelihood that elevated pulmonary vascular resistance (PVR) will become fixed, preventing successful repair. However, a small study suggests that there are some select adolescent and adult patients with severe pulmonary hypertension (defined by systolic PA pressure &gt;70 percent systemic systolic pressure) and uncorrected VSD (with or without great artery anomalies) who may benefit from a palliative procedure, such as a pulmonary arterial band to improve functional class and provide a small chance of eventual total repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/24\">",
"     24",
"    </a>",
"    ]. Irreversible pulmonary vascular disease develops earlier in children with Trisomy 21; large VSDs in such children should be repaired by three to four months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=see_link\">",
"     \"Management of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare case of a large VSD that persists into late childhood without intervention, the increase in PA blood flow from persistent left-to-right shunting results in the development of pulmonary vascular remodeling and histologic evidence of pulmonary arteriolar intimal and medial hypertrophy. The resulting elevated PA vascular resistance leads to RV pressure overload and RV hypertrophy. When PVR exceeds systemic vascular resistance, the ultimate reversal of flow with right-to-left shunting causes cyanosis. This condition is called Eisenmenger syndrome. It is a serious, and generally irreversible, medical problem resulting in death as early as the third decade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants with VSD present in the neonatal period. However, the clinical presentation varies depending upon the size of the defect and may range from an isolated murmur that is detected incidentally at a health supervision visit to severe heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms begin to develop when pulmonary vascular resistance (PVR) declines sufficiently to permit left-to-right shunting. Thus, the typical presentation of a small VSD in a neonate involves the detection of a cardiac murmur at four to ten days of life. Other symptoms are usually absent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/2\">",
"     2",
"    </a>",
"    ]. Mild tachycardia and tachypnea may develop by two to eight weeks of age if the defect is larger than small, particularly with an intercurrent respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal decline in PVR can be delayed in infants with moderate and large VSDs. Thus, murmurs may not be detected in such infants until several weeks postnatally [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/2\">",
"     2",
"    </a>",
"    ]. Infants with moderate or large VSDs also may present with tachypnea, increased work of breathing, poor weight gain or failure to thrive, and diaphoresis, particularly with feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3,26,27\">",
"     3,26,27",
"    </a>",
"    ]. The severity of symptoms depends upon the size of the shunt, and the ability of the left ventricle (LV) to maintain systemic output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with small, restrictive VSDs usually remain asymptomatic. In contrast, infants with moderate to large VSDs usually manifest signs of heart failure by three to four weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. These include",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachypnea (from increased pulmonary blood flow)",
"     </li>",
"     <li>",
"      Poor feeding (appears hungry but tires easily; sweats with feeds)",
"     </li>",
"     <li>",
"      Poor weight gain (prolonged and severe failure may also affect linear growth and head circumference) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Hepatomegaly",
"     </li>",
"     <li>",
"      Pulmonary rales, grunting, and retractions (if heart failure is marked)",
"     </li>",
"     <li>",
"      Pallor (from peripheral vasoconstriction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cardiac examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Precordial palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precordial palpation provides information that is helpful in determining the size of the left-to-right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with small VSDs and a large pressure differential between the LV and RV, a thrill",
"      <span class=\"nowrap\">",
"       (4/6",
"      </span>",
"      murmur) may be palpated in the third or fourth left intercostal space (LICS) at the left sternal border; if the defect is subpulmonic, the thrill is best palpated in the second or first and second LICS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Infants with moderate or large defects may develop an RV heave as PVR falls during the first few weeks of life and left-to-right shunt increases; the precordium becomes more active as the left-to-right shunt increases in size",
"     </li>",
"     <li>",
"      The dilated pulmonary trunk and pulmonary closure may be palpable in the second LICS of patients with large VSDs",
"     </li>",
"     <li>",
"      As LV output increases to compensate for the left-to-right shunt, vigorous LV contraction is reflected in a prominent apical impulse",
"     </li>",
"     <li>",
"      As the heart enlarges, the cardiac apex is displaced outside the mid-clavicular line",
"     </li>",
"     <li>",
"      As PVR increases, the size of the left-to-right shunt decreases and LV activity decreases",
"     </li>",
"     <li>",
"      Vigorous precordial activity and a dynamic LV impulse, particularly in the left lateral recumbent position may indicate the development of aortic regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aortic regurgitation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Systolic murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The character and duration of the systolic murmur are helpful in evaluating the size of the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The murmur of a small defect is classically described as a 2 to",
"      <span class=\"nowrap\">",
"       3/6",
"      </span>",
"      low-pitched harsh holosystolic murmur best heard at the left mid- to lower-sternal border; subpulmonic defects are best heard at the left upper sternal border [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During spontaneous closure the holosystolic murmur may shorten, occurring only in early systole, before disappearing altogether [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The murmur of small muscular or perimuscular VSDs may occur only in early systole since the contraction of the septum during systole may close the defect.",
"     </li>",
"     <li>",
"      The murmur of moderate defects, usually evident within two to three days of birth, is holosystolic, high frequency, grade",
"      <span class=\"nowrap\">",
"       2/6",
"      </span>",
"      or louder, and heard best in the 3rd or 4th LICS; the quality of the murmur may change as PVR falls.",
"     </li>",
"     <li>",
"      In infants who have large VSDs, as PVR approaches systemic levels, the holosystolic murmur shortens and softens before disappearing altogether.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Diastolic murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of diastolic murmurs in infants usually indicates increased left-to-right shunting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diastolic rumble due to increased flow across the mitral valve may be heard at the apex in infants with moderate to large VSDs and Qp:Qs &gt;2:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/27,31\">",
"       27,31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effects on systemic circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high-frequency decrescendo murmur beginning with the first component of the second heart sound and best heard at the mid- to-lower sternal border suggests the development of aortic regurgitation secondary to prolapse of an aortic cusp through either a perimembranous or a subpulmonic defect. Patients with such murmurs usually require early surgery. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aortic regurgitation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"       \"Management of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An early diastolic decrescendo murmur at the mid- left sternal border in patients with elevated pulmonary artery pressures suggests pulmonary regurgitation. Patients with such murmurs should be evaluated for elevated pulmonary vascular resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Second heart sound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity and degree of splitting of the second heart sound provide useful information about the size of the defect and the elevation of PVR, although these features may be difficult to appreciate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. The second heart sound may be obscured by a holosystolic murmur and splitting may be difficult to appreciate when the heart rate is increased.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A loud second sound at the left upper sternal border indicates that pulmonary arterial and right ventricular pressures are elevated, suggesting that the defect is large.",
"     </li>",
"     <li>",
"      A well-split second sound suggests that PVR is not markedly increased, whereas a narrow or single accentuated sound indicates that PVR is elevated",
"     </li>",
"     <li>",
"      Exaggerated splitting, reflecting an increase in right ventricular volume and prolonged systole, may be detected in infants with moderate to large defects and PVR less than systemic vascular resistance",
"     </li>",
"     <li>",
"      A wide, but not fixed splitting of the second heart sound may be noted in patients who have right bundle branch block as a complication of surgical closure of VSD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Arterial pulses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As LV output increases to compensate for the left-to-right shunt, vigorous LV contraction is reflected in brisk arterial pulses; the arterial pulse diminishes as PVR increases",
"     </li>",
"     <li>",
"      If LV failure develops, the arterial pulse diminishes and pulsus alternans may be present (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"       \"Examination of the arterial pulse\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bounding (\"water-hammer\") pulses suggest the development of aortic regurgitation (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Aortic regurgitation'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pulmonary vascular disease, discussed above, complications of VSDs may include the development of endocarditis, aortic regurgitation, subaortic stenosis, RV outflow obstruction, and atrial shunting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis is an uncommon complication (occurring in less than 1 percent to 3 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/17,32-38\">",
"     17,32-38",
"    </a>",
"    ]. Surgical closure reduces the risk, even in patients who have residual defects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the risk of endocarditis is increased in the immediate postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Structural heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of infective endocarditis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis to prevent infective endocarditis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"     \"Management of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve prolapse and regurgitation may occur in subpulmonic and membranous defects. This complication is more common in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], has peak onset between five and nine years of age and seldom occurs before two or after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In membranous defects, aortic regurgitation is associated with sagging or herniation of the right coronary cusp alone or in conjunction with the noncoronary cusp [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. Herniation into the right ventricle (RV) outflow tract may cause obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] and herniation through the VSD may reduce the left-to-right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/41,53\">",
"     41,53",
"    </a>",
"    ]. In subpulmonic VSDs, the aortic and pulmonary valves are in fibrous continuity with each other [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/54\">",
"     54",
"    </a>",
"    ]. The aortic valve is unsupported and the right and noncoronary sinuses move into the right ventricular outflow tract causing aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/41,52,53\">",
"     41,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with VSD and aortic regurgitation, the left ventricle (LV) is doubly overloaded because of both the regurgitant volume from the aorta and the increased volume returning to the left atrium from the pulmonary circulation. The natural history is one of gradual progression. The risk of infective endocarditis is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Structural heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features include neck pulsations, chest pain, diaphoresis, vigorous precordial movement (particularly in the left lateral recumbent position) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/16\">",
"     16",
"    </a>",
"    ], bounding pulses, wide pulse pressure, and early diastolic murmur (in addition to the holosystolic murmur of the VSD). The diastolic murmur is a high-frequency decrescendo murmur that begins with the first component of the second heart sound and is best heard at the mid- to-lower sternal border. Radiographic features include enlargement of the LV that is out of proportion to the evidence of left-to-right shunt and a prominent ascending aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Subaortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with membranous VSDs can occasionally develop discrete fibrous or fibromuscular subaortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Surgical resection is undertaken, but the degree of obstruction at which intervention is recommended varies between both physicians and institutions. The LV outflow tract obstruction generally is progressive and there is potential for damage to the aortic valve. Long-term follow-up after surgical resection is necessary because recurrence is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     RV outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with membranous defects may develop hypertrophy of muscle in the right ventricular infundibulum, which, over a variable period of time, may result in narrowing of the outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3,41,59\">",
"     3,41,59",
"    </a>",
"    ]. Double chambered RV (DCRV) results when anomalous bands of muscle divide the RV cavity into two chambers. DCRV may develop in patients with membranous VSD (whether or not they have undergone surgical repair) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/60-65\">",
"     60-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstruction to RV outflow results in increased resistance to RV ejection and decreased left-to right shunt. Initially this may account for improvement of cardiac failure in infants with restrictive VSDs. However, with severe muscle hypertrophy, right-to-left shunting may develop, with clinical features similar to those in tetralogy of Fallot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     LV to RA shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased left atrial pressure and consequent enlargement may cause stretching of the atrial septum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. This may lead to incompetence of the foramen ovale and possible herniation of the lower margin of the fossa ovalis into the right atrium (RA), resulting in secondary left ventricular-to-right atrial (LV-RA) shunting. Although such LV-RA shunts (Gerbode defect) are usually small, they can be of sufficient volume to modify the clinical features, accelerating the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ]. This is because atrial shunting prevents the increase in LV end-diastolic pressure which is necessary to increase LV output and maintain systemic blood flow. The increased diastolic volume load is placed on the already pressure overloaded RV, and RV failure dominates the clinical picture.",
"   </p>",
"   <p>",
"    Patients with LV-RA shunts may still have spontaneous closure of their VSDs but appear to be at increased risk for endocarditis. This was illustrated in a review from a single center of 68 patients with LV-RA atrial shunting who were not operated on before six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/66\">",
"     66",
"    </a>",
"    ]. Onset of LV-RA shunting was at a mean age of 5.8 &plusmn; 3.3 years. Over a mean follow-up time of 17 &plusmn; 5 years (range 6 to 28 years), spontaneous closure of the VSD occurred in five patients. The patients in this study had a higher risk of endocarditis compared to the reported risk in patients with VSD alone (8.7 versus 1 to 3 percent). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Endocarditis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of isolated VSD is usually suspected clinically and is confirmed with echocardiography. Experienced pediatric cardiologists are often able to make the diagnosis clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/25\">",
"     25",
"    </a>",
"    ], but may choose to obtain an echocardiogram to exclude associated lesions, to locate the defect, and to estimate its size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with a possible VSD usually begins with an electrocardiogram (ECG) and possibly a chest radiograph. This is usually followed by echocardiography to confirm the diagnosis, identify the location of the defect(s) and any associated lesions, and to estimate the size of the shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic (ECG) findings, which represent the increased volume and pressure loads on the left and right ventricles, vary with the size of the VSD, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ECG is normal in patients with small VSDs.",
"     </li>",
"     <li>",
"      In patients with moderate or large left-to-right shunts the ECG may demonstrate the left atrial enlargement and left ventricular hypertrophy (LVH) caused by the increased blood volume returning to the left heart.",
"     </li>",
"     <li>",
"      When the defect is large enough to maintain elevated right ventricle (RV) pressure, the ECG demonstrates RV hypertrophy in addition to LVH.",
"     </li>",
"     <li>",
"      In patients with pulmonary vascular resistance (PVR) elevations sufficient to reverse the direction of the shunt, the ECG demonstrates evidence of right atrial enlargement in addition to RVH; LVH is no longer present.",
"     </li>",
"     <li>",
"      Patients who have undergone surgical closure may develop right bundle branch block (complete or incomplete).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have marked RVH require further evaluation to determine the cause. Possibilities include elevated PVR, pulmonary stenosis, or double-chambered RV, and management varies accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic findings vary depending upon the size of the left-to-right shunt and the state of the pulmonary vascular bed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In small defects, the radiograph is usually normal.",
"     </li>",
"     <li>",
"      In moderate to large defects with increased left-to-right shunts, the pulmonary vascular markings are increased, and the left atrium, LV, and pulmonary artery may be enlarged.",
"     </li>",
"     <li>",
"      As PVR increases, RV enlargement becomes more prominent and the LV decreases in size; anterior bulging of the lower sternum may be present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is usually performed to confirm the diagnosis in neonates with a prominent systolic murmur since a number of structural cardiac lesions present with systolic murmurs in the first few weeks of life. Two-dimensional and Doppler echocardiographies are useful in identifying the location of the defect and estimating the size of the shunt to formulate a plan for follow-up care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of isolated ventricular septal defects in infants and children\", section on 'Schedule of follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion on the use of echocardiography in assessing VSDs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=see_link\">",
"     \"Echocardiographic evaluation of ventricular septal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization, once commonly performed in the evaluation of infants with VSD, is now rarely performed. In some clinical situations, a catheterization may help assess the need for closure (Qp:Qs) or plan perioperative management (PVR, testing of vasodilators) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/19/8506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/26/4514?source=see_link\">",
"       \"Patient information: Ventricular septal defect (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation and natural history of isolated ventricular septal defects in children depends upon the size of the defect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small, restrictive defects usually are detected by the presence of a holosystolic murmur at the mid-to lower left sternal border. These defects rarely cause symptoms, and often close spontaneously. Clinical manifestations of closure include shortening and ultimate disappearance of the murmur, and the continued lack of symptoms.",
"     </li>",
"     <li>",
"      Infants who have moderate defects with low pulmonary vascular resistance (PVR) usually present with heart failure and poor growth in infancy. Cardiac examination reveals a dynamic precordium, a holosystolic murmur (with or without a thrill) at the mid- to lower left sternal border, and increased second component of the second heart sound. The presence of a diastolic murmur at the apex indicates a ratio of pulmonary to systemic blood flow (Qp:Qs) of at least 2:1. The presence of a diastolic murmur at the mid- to-lower sternal border may indicate aortic or pulmonary regurgitation and warrants further evaluation. Moderate defects decrease in size with time and may close spontaneously. In the interim, signs and symptoms of cardiac failure can usually be controlled with pharmacologic and nutritional interventions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"       \"Management of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants who have large, nonrestrictive defects with elevated PVR present in infancy with heart failure and failure to thrive. Examination findings are similar to those in infants with moderate defects, but less responsive to interventions. In infants with large defects, irreversible pulmonary vascular changes may begin within 6 to 12 months and may be advanced by 2 to 3 years of age. Large defects may decrease in size, but rarely close completely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"       \"Management of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In some infants with large VSDs, PVR remains sufficiently elevated to limit the shunt. The clinical presentation in these infants may be more subtle. If these infants are not treated, PVR progressively increases and right-to-left shunting may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Clinical pearls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major conclusions that arise from the physical examination, ECG, and chest radiograph can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The finding of a typical loud systolic murmur (grade 3 to 6 over 6), with normal precordial activity, and a normal ECG and chest radiograph is associated with a small, hemodynamically insignificant VSD.",
"     </li>",
"     <li>",
"      Patients with a VSD and ECG evidence of right ventricular hypertrophy require evaluation to determine the cause (eg, pulmonary hypertension, pulmonary stenosis, or double-chambered right ventricle).",
"     </li>",
"     <li>",
"      The development of a new diastolic murmur of semilunar valve insufficiency mandates further evaluation. Patients with aortic regurgitation usually require early surgery, whereas patients with pulmonary regurgitation should be evaluated for increased pulmonary vascular resistance.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/1\">",
"      Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/2\">",
"      Van Praagh R, Geva T, Kreutzer J. Ventricular septal defects: how shall we describe, name and classify them? J Am Coll Cardiol 1989; 14:1298.",
"     </a>",
"    </li>",
"    <li>",
"     Rudolph AM. Ventricular Septal Defect. In: Congenital Diseases of the Heart: Clinical-Physiological Considerations, Rudolph AM (Ed), Futura Publishing Company, New York 2001. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/4\">",
"      Moe DG, Guntheroth WG. Spontaneous closure of uncomplicated ventricular septal defect. Am J Cardiol 1987; 60:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/5\">",
"      Du ZD, Roguin N, Wu XJ. Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates. Cardiol Young 1998; 8:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/6\">",
"      Varghese PJ, Izukawa T, Celermajer J, et al. Aneurysm of the membranous ventricular septum. A method of spontaneous closure of small ventricular septal defect. Am J Cardiol 1969; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/7\">",
"      Freedom RM, White RD, Pieroni DR, et al. The natural history of the so-called aneurysm of the membranous ventricular septum in childhood. Circulation 1974; 49:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/8\">",
"      Misra KP, Hildner FJ, Cohen LS, et al. Aneurysm of the membranous ventricular septum. A mechanism for spontaneous closure of ventricular septal defect. N Engl J Med 1970; 283:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/9\">",
"      Ramaciotti C, Keren A, Silverman NH. Importance of (perimembranous) ventricular septal aneurysm in the natural history of isolated perimembranous ventricular septal defect. Am J Cardiol 1986; 57:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/10\">",
"      Anderson RH, Lenox CC, Zuberbuhler JR. Mechanisms of closure of perimembranous ventricular septal defect. Am J Cardiol 1983; 52:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/11\">",
"      TITUS JL, DAUGHERTY GW, EDWARDS JE. Anatomy of the atrioventricular conduction system in ventricular septal defect. Circulation 1963; 28:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/12\">",
"      Soto B, Becker AE, Moulaert AJ, et al. Classification of ventricular septal defects. Br Heart J 1980; 43:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/13\">",
"      Ando M, Takao A. Pathological anatomy of ventricular septal defect associated with aortic valve prolapse and regurgitation. Heart Vessels 1986; 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/14\">",
"      Roguin N, Du ZD, Barak M, et al. High prevalence of muscular ventricular septal defect in neonates. J Am Coll Cardiol 1995; 26:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/15\">",
"      Miyake T, Shinohara T, Inoue T, et al. Spontaneous closure of muscular trabecular ventricular septal defect: comparison of defect positions. Acta Paediatr 2011; 100:e158.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Ventricular septal defect. In: The Clinical Recognition of Congenital Heart Disease, 5th, W.B. Saunders Company, Philadelphia 2003. p.311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/17\">",
"      Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87:I38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/18\">",
"      Gabriel HM, Heger M, Innerhofer P, et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol 2002; 39:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/19\">",
"      Neumayer U, Stone S, Somerville J. Small ventricular septal defects in adults. Eur Heart J 1998; 19:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/20\">",
"      Shirali GS, Smith EO, Geva T. Quantitation of echocardiographic predictors of outcome in infants with isolated ventricular septal defect. Am Heart J 1995; 130:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/21\">",
"      Van Hare GF, Soffer LJ, Sivakoff MC, Liebman J. Twenty-five-year experience with ventricular septal defect in infants and children. Am Heart J 1987; 114:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/22\">",
"      Onat T, Ahunbay G, Batmaz G, Celebi A. The natural course of isolated ventricular septal defect during adolescence. Pediatr Cardiol 1998; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/23\">",
"      Kleinman CS, Tabibian M, Starc TJ, et al. Spontaneous regression of left ventricular dilation in children with restrictive ventricular septal defects. J Pediatr 2007; 150:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/24\">",
"      Lin MT, Chen YS, Huang SC, et al. Alternative approach for selected severe pulmonary hypertension of congenital heart defect without initial correction--palliative surgical treatment. Int J Cardiol 2011; 151:313.",
"     </a>",
"    </li>",
"    <li>",
"     Gumbiner CH, Takao A. Ventricular septal defect. In: The Science and Practice of Pediatric Cardiology, 2nd, Garson A, Bricker JT, Fisher DJ, Neish SR (Eds), Williams &amp; Wilkins, Baltimore 1998. p.1119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/26\">",
"      Alter BP, Czapek EE, Rowe RD. Sweating in congenital heart disease. Pediatrics 1968; 41:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/27\">",
"      FYLER DC, RUDOLPH AM, WITTENBORG MH, NADAS AS. Ventricular septal defect in infants and children; a correlation of clinical, physiologic, and autopsy data. Circulation 1958; 18:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/28\">",
"      Miller RH, Schiebler GL, Grumbar P, Krovetz LJ. Relation of hemodynamics to height and weight percentiles in children with ventricular septal defects. Am Heart J 1969; 78:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/29\">",
"      Levy RJ, Rosenthal A, Miettinen OS, Nadas AS. Determinants of growth in patients with ventricular septal defect. Circulation 1978; 57:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/30\">",
"      EVANS JR, ROWE RD, KEITH JD. Spontaneous closure of ventricular septal defects. Circulation 1960; 22:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/31\">",
"      Nadas AS, Ellison RC. Phonocardiographic analysis of diastolic flow murmurs in secundum atrial septal defect and ventricular septal defect. Br Heart J 1967; 29:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/32\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/33\">",
"      Frontera-Izquierdo P, Cabezuelo-Huerta G. Natural and modified history of isolated ventricular septal defect: a 17-year study. Pediatr Cardiol 1992; 13:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/34\">",
"      Otterstad JE, Nitter-Hauge S, Myhre E. Isolated ventricular septal defect in adults. Clinical and haemodynamic findings. Br Heart J 1983; 50:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/35\">",
"      Shah P, Singh WS, Rose V, Keith JD. Incidence of bacterial endocarditis in ventricular septal defects. Circulation 1966; 34:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/36\">",
"      KAPLAN S, DAOUD GI, BENZING G 3rd, et al. Natural history of ventricular septal defect. Am J Dis Child 1963; 105:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/37\">",
"      Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 1991; 68:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/38\">",
"      KIRKLIN JW, DUSHANE JW. INDICATIONS FOR REPAIR OF VENTRICULAR SEPTAL DEFECTS. Am J Cardiol 1963; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/39\">",
"      Johnson DH, Rosenthal A, Nadas AS. A forty-year review of bacterial endocarditis in infancy and childhood. Circulation 1975; 51:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/40\">",
"      Linde LM, Heins HC. Bacterial endocarditis following surgery for congenital heart disease. New Engl J Med 1960; 65:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/41\">",
"      NADAS AS, THILENIUS OG, LAFARGE CG, HAUCK AJ. VENTRICULAR SEPTAL DEFECT WITH AORTIC REGURGITATION: MEDICAL AND PATHOLOGIC ASPECTS. Circulation 1964; 29:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/42\">",
"      Momma K, Toyama K, Takao A, et al. Natural history of subarterial infundibular ventricular septal defect. Am Heart J 1984; 108:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/43\">",
"      HALLORAN KH, TALNER NS, BROWNE MJ. A STUDY OF VENTRICULAR SEPTAL DEFECT ASSOCIATED WITH AORTIC INSUFFICIENCY. Am Heart J 1965; 69:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/44\">",
"      Mori K, Matsuoka S, Tatara K, et al. Echocardiographic evaluation of the development of aortic valve prolapse in supracristal ventricular septal defect. Eur J Pediatr 1995; 154:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/45\">",
"      Craig BG, Smallhorn JF, Burrows P, et al. Cross-sectional echocardiography in the evaluation of aortic valve prolapse associated with ventricular septal defect. Am Heart J 1986; 112:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/46\">",
"      Menahem S, Johns JA, del Torso S, et al. Evaluation of aortic valve prolapse in ventricular septal defect. Br Heart J 1986; 56:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/47\">",
"      Rhodes LA, Keane JF, Keane JP, et al. Long follow-up (to 43 years) of ventricular septal defect with audible aortic regurgitation. Am J Cardiol 1990; 66:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/48\">",
"      Somerville J, Brandao A, Ross DN. Aortic regurgitation with ventricular septal defect. Surgical management and clinical features. Circulation 1970; 41:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/49\">",
"      B&uuml;tter A, Duncan W, Weatherdon D, et al. Aortic cusp prolapse in ventricular septal defect and its association with aortic regurgitation--appropriate timing of surgical repair and outcomes. Can J Cardiol 1998; 14:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/50\">",
"      Leung MP, Chau KT, Chiu C, et al. Intraoperative TEE assessment of ventricular septal defect with aortic regurgitation. Ann Thorac Surg 1996; 61:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/51\">",
"      Chung KJ, Manning JA. Ventricular septal defect associated with aortic insufficiency: medical and surgical management. Am Heart J 1974; 87:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/52\">",
"      Van Praagh R, McNamara JJ. Anatomic types of ventricular septal defect with aortic insufficiency. Diagnostic and surgical considerations. Am Heart J 1968; 75:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/53\">",
"      Plauth WH Jr, Braunwald E, Rockoff SD, et al. Ventricular septal defect and aortic regurgitation: clinical, hemodynamic and surgical considerations. Am J Med 1965; 39:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/54\">",
"      Griffin ML, Sullivan ID, Anderson RH, Macartney FJ. Doubly committed subarterial ventricular septal defect: new morphological criteria with echocardiographic and angiocardiographic correlation. Br Heart J 1988; 59:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/55\">",
"      Kitchiner D, Jackson M, Malaiya N, et al. Morphology of left ventricular outflow tract structures in patients with subaortic stenosis and a ventricular septal defect. Br Heart J 1994; 72:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/56\">",
"      Chung KJ, Fulton DR, Kreidberg MB, et al. Combined discrete subaortic stenosis and ventricular septal defect in infants and children. Am J Cardiol 1984; 53:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/57\">",
"      Vogel M, Freedom RM, Brand A, et al. Ventricular septal defect and subaortic stenosis: an analysis of 41 patients. Am J Cardiol 1983; 52:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/58\">",
"      Fisher DJ, Snider AR, Silverman NH, Stanger P. Ventricular septal defect with silent discrete subaortic stenosis. Pediatr Cardiol 1982; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/59\">",
"      GASUL BM, DILLON RF, VRLA V, HAIT G. Ventricular septal defects; their natural transformation into the cyanotic or noncyanotic type of tetralogy of Fallot. J Am Med Assoc 1957; 164:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/60\">",
"      Galal O, Al-Halees Z, Solymar L, et al. Double-chambered right ventricle in 73 patients: spectrum of the disease and surgical results of transatrial repair. Can J Cardiol 2000; 16:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/61\">",
"      Singh M, Agarwala MK, Grover A, et al. Clinical, echocardiographic, and angiographic profile of patients with double-chambered right ventricle: experience with 48 cases. Angiology 1999; 50:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/62\">",
"      Cil E, Sara&ccedil;lar M, Ozkutlu S, et al. Double-chambered right ventricle: experience with 52 cases. Int J Cardiol 1995; 50:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/63\">",
"      Simpson WF Jr, Sade RM, Crawford FA, et al. Double-chambered right ventricle. Ann Thorac Surg 1987; 44:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/64\">",
"      Maron BJ, Ferrans VJ, White RI Jr. Unusual evolution of acquired infundibular stenosis in patients with ventricular septal defect. Clinical and morphologic observations. Circulation 1973; 48:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/65\">",
"      Massin M. [Development of double-chambered right ventricle after surgical closure of a ventricular septal defect]. Ann Cardiol Angeiol (Paris) 1998; 47:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/19/8506/abstract/66\">",
"      Wu MH, Wang JK, Lin MT, et al. Ventricular septal defect with secondary left ventricular-to-right atrial shunt is associated with a higher risk for infective endocarditis and a lower late chance of closure. Pediatrics 2006; 117:e262.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5787 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8506=[""].join("\n");
var outline_f8_19_8506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Membranous defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Subpulmonic (outlet)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AV canal (inlet)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscular defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Size of defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Changes in PVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effects on pulmonary circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effects on systemic circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Small VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Moderate VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Large VSD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Precordial palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Systolic murmurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Diastolic murmurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Second heart sound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Arterial pulses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Subaortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - RV outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - LV to RA shunting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Clinical pearls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5787|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/14/8419\" title=\"figure 1\">",
"      Interventricular septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/7/42096\" title=\"figure 2\">",
"      Doppler interrogation VSD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=related_link\">",
"      Echocardiographic evaluation of ventricular septal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=related_link\">",
"      Management of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=related_link\">",
"      Management of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/26/4514?source=related_link\">",
"      Patient information: Ventricular septal defect (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_19_8507="Ankle foot orthosis";
var content_f8_19_8507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Semi-rigid ankle foot orthosis (AFO)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Brands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hinged ankle strap",
"       </td>",
"       <td>",
"        Modified orthotic footplate provides critical foot and arch support while resisting inversion and eversion",
"       </td>",
"       <td>",
"        Active Ankle, Bledsoe Ultimate Ankle Brace, Atom Ankle by Swede-O",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ankle gauntlet",
"       </td>",
"       <td>",
"        Removable plastic stabilizers insert into pockets on either side to help protect against inversion and eversion",
"       </td>",
"       <td>",
"        Swede-O, Royce ExoForm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible stirrup",
"       </td>",
"       <td>",
"        Standard ankle brace allows for unobstructed motion in plantar and dorsiflexion",
"       </td>",
"       <td>",
"        AirCast",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8507=[""].join("\n");
var outline_f8_19_8507=null;
var title_f8_19_8508="Lung ca screening guidelines";
var content_f8_19_8508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for lung cancer screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organization",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        American College of Chest Physicians/American Society of Clinical Oncology",
"       </td>",
"       <td>",
"        Recommends annual low-dose CT scan screening for high-risk individuals (age 55 to 74 years with 30 pack-year history of smoking and current smoker or quit within past 15 years).",
"       </td>",
"       <td>",
"        2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        American Association of Thoracic Surgery (AATS)",
"       </td>",
"       <td>",
"        Recommends annual low-dose CT scan screening for high-risk individuals (age 55 to 74 years with 30 pack-year history of smoking and current smoker or quit within past 15 years) or age 50 with cummulative risk &gt;5 percent over next five years.",
"       </td>",
"       <td>",
"        2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        National Comprehensive Cancer Network",
"       </td>",
"       <td>",
"        Recommends annual low-dose CT scan screening for high-risk individuals (age 55 to 74 years with 30 pack-year history of smoking or 20 pack-year history with an additional risk factor).",
"       </td>",
"       <td>",
"        2011",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        American Cancer Society",
"       </td>",
"       <td>",
"        Recommends annual low-dose CT scan screening for high-risk individuals (age 55 to 74 years with 30 pack-year history of smoking and current smoker or quit within past 15 years). Informed individual decision making before testing.",
"       </td>",
"       <td>",
"        2013",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        US Preventive Services Task Force",
"       </td>",
"       <td>",
"        Evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low-dose computerized tomography, chest x-ray, sputum cytology, or a combination of these tests.",
"       </td>",
"       <td>",
"        2004",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canadian Task Force on the Periodic Health Examination",
"       </td>",
"       <td>",
"        Recommends against the use of chest x-ray in asymptomatic persons. Evidence is insufficient to recommend for or against screening with spiral CT in asymptomatic persons.",
"       </td>",
"       <td>",
"        2003",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8508=[""].join("\n");
var outline_f8_19_8508=null;
var title_f8_19_8509="CYE MTX regimen prevent GVHD";
var content_f8_19_8509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Triple drug prophylaxis for acute graft-versus-host disease after hematopoietic stem cell transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Day",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Route",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -2 to +3",
"       </td>",
"       <td>",
"        5 mg/kg*",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        IV QD by infusion over 20 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +4 to +14",
"       </td>",
"       <td>",
"        3 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        IV QD by infusion over 20 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +15 to +35",
"       </td>",
"       <td>",
"        3.75 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        IV QD by infusion over 20 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +36 to +83",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +84 to +97",
"       </td>",
"       <td>",
"        4 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +98 to +119",
"       </td>",
"       <td>",
"        3 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +120 to +180",
"       </td>",
"       <td>",
"        2 mg/kg",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Methotrexate&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Regimen A",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Regimen B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Day",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle3\">",
"        Day",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose and route",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +1",
"       </td>",
"       <td>",
"        15 mg/m2, IV",
"       </td>",
"       <td>",
"        +1",
"       </td>",
"       <td>",
"        15 mb/m2, IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +3",
"       </td>",
"       <td>",
"        10 mg/m2, IV",
"       </td>",
"       <td>",
"        +3",
"       </td>",
"       <td>",
"        10 mg/m2, IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +6",
"       </td>",
"       <td>",
"        10 mg/m2, IV",
"       </td>",
"       <td>",
"        +6",
"       </td>",
"       <td>",
"        10 mg/m2, IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +11",
"       </td>",
"       <td>",
"        10 mg/m2, IV",
"       </td>",
"       <td>",
"        +11",
"       </td>",
"       <td>",
"        Placebo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Without methylprednisolone",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        With",
"methylprednisolone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle3\">",
"        Day",
"       </td>",
"       <td class=\"subtitle3\">",
"        Dose and route",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +7 to +14",
"       </td>",
"       <td>",
"        0.25 mg/kg IV BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +15 to +28",
"       </td>",
"       <td>",
"        0.5 mg/kg IV BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +29 to +42",
"       </td>",
"       <td>",
"        0.4 mg/kg PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +43 to +56",
"       </td>",
"       <td>",
"        0.25 mg/kg PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +57 to +119",
"       </td>",
"       <td>",
"        0.1 mg/kg PO BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +120 to +180",
"       </td>",
"       <td>",
"        0.1 mg/kg PO QD",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients receiving a matched unrelated transplant do not receive the loading dose (ie, cyclosporine starts on day -2 at 3 mg/kg IV QD by infusion over 20 hours).",
"     <br>",
"      &bull; Note the different dosing schedules of methotrexate in the two regimens.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8509=[""].join("\n");
var outline_f8_19_8509=null;
var title_f8_19_8510="Antimalarial ppx adults";
var content_f8_19_8510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug regimens for prophylaxis against malaria in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tablet size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency*",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Initiation",
"        </p>",
"        <p>",
"         (time before first exposure to malaria)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Discontinuation",
"        </p>",
"        <p>",
"         (time after last exposure)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Use in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Areas with chloroquine-resistant Plasmodium falciparum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atovaquone-proguanil (Malarone)",
"       </td>",
"       <td>",
"        250 mg atovaquone and 100 mg proguanil",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        7 days",
"       </td>",
"       <td>",
"        No; insufficient data on use in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mefloquine hydrochloride (Lariam and generic agents)",
"       </td>",
"       <td>",
"        250 mg salt (228 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        3 weeks preferable; 2 weeks acceptable",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents)",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        No; teratogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Areas with chloroquine-sensitive Plasmodium falciparum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chloroquine phosphate (Aralen and generic agents)",
"       </td>",
"       <td>",
"        500 mg salt (300 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        1-2 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxychloroquine sulfate (Plaquenil)",
"       </td>",
"       <td>",
"        400 mg salt (310 mg base)",
"       </td>",
"       <td>",
"        One table orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        1-2 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atovaquone-proguanil (Malarone)",
"       </td>",
"       <td>",
"        250 mg atovaquone and 100 mg proguanil",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        7 days",
"       </td>",
"       <td>",
"        No; insufficient data on use in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mefloquine hydrochloride (Lariam and generic agents)",
"       </td>",
"       <td>",
"        250 mg salt (228 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        3 weeks preferable; 2 weeks acceptable",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents)",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        No; teratogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Areas with P. vivax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primaquine phosphate (appropriate prophylaxis for short duration travel to areas with principally P. vivax)",
"       </td>",
"       <td>",
"        26.3 mg salt (15 mg base)",
"       </td>",
"       <td>",
"        Two tablets orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        7 days",
"       </td>",
"       <td>",
"        No; contraindicated because of potential toxicity for fetal erythrocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chloroquine phosphate (Aralen and generic agents)",
"       </td>",
"       <td>",
"        500 mg salt (300 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        1-2 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxychloroquine sulfate (Plaquenil)",
"       </td>",
"       <td>",
"        400 mg salt (310 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        1-2 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atovaquone-proguanil (Malarone)",
"       </td>",
"       <td>",
"        250 mg atovaquone and 100 mg proguanil",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        7 days",
"       </td>",
"       <td>",
"        No; insufficient data on use in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mefloquine hydrochloride (Lariam and generic agents)",
"       </td>",
"       <td>",
"        250 mg salt (228 mg base)",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once weekly",
"       </td>",
"       <td>",
"        3 weeks preferable; 2 weeks acceptable",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents)",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        One tablet orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        1-2 days",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        No; teratogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Presumptive antirelapse therapy (to prevent relapse due to P. vivax or P. ovale)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primaquine phosphate",
"       </td>",
"       <td>",
"        26.3 mg salt (15 mg base)",
"       </td>",
"       <td>",
"        Two tablets orally",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"       <td>",
"        As soon as possible following exposure for which another prophylactic drug taken",
"       </td>",
"       <td>",
"        14 days",
"       </td>",
"       <td>",
"        No; contraindicated because of potential toxicity for fetal erythrocytes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Drugs administered once daily should be taken at the same time each day; drugs administered once weekly should be taken on the same day each week.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     1. Hill, DR, Ericsson, CD, Pearson, RD, et al. The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     <br>",
"      2. Freedman, DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603-612.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8510=[""].join("\n");
var outline_f8_19_8510=null;
var title_f8_19_8511="CAV lesion types";
var content_f8_19_8511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiac allograft vasculopathy lesion types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic abnormalities in transplant coronary vascular disease.",
"    <br>",
"     Type A lesion: discrete, tubular or multiple stenoses.",
"     <br>",
"      Type B",
"      <sub>",
"       1",
"      </sub>",
"      lesion: abrupt onset with distal diffuse concentric narrowing and obliterated vessels.",
"      <br>",
"       Type B",
"       <sub>",
"        2",
"       </sub>",
"       lesion: gradual, concentric tapering with distal portion having some residual lumen.",
"       <br>",
"        Type C lesion: narrowed irregular distal branches with terminations that are often nontapered and squared off, ending abruptly.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced from: Gao, SZ, Alderman, EL, Schroeder, JS, et al. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12:334. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_19_8511=[""].join("\n");
var outline_f8_19_8511=null;
               